3rd Annual EUROPEAN LIFE SCIENCE CEO FORUM · audience of over 400 investors, analysts & media,...

REGIONAL PARTNERSORGANISERS

AWARDS

PARTNERING ORGANISATIONSSPEAKERS

PRESENTING COMPANIES

WELCOM

ESPONSORS

3rd Annual

EUROPEAN LIFE SCIENCE CEO FORUM

for PARTNERING & INVESTING

www.sachsforum.com

11-12 February 2010ConventionPoint, Zurich, Switzerland

Conference Guide

EU

RO

PE

AN

L

IF

E

SC

IE

NC

E

CE

O

FO

RU

M


AWARDS



WELCOM

ESPONSORS

WELCOM

E

Welcome

next

Request for PresentationsPlease use the agenda to mark off presentations that you are interested in and email your request to [email protected]. We will endeavour to send you the requested presentations as soon as we have been granted permission to do so by that specifi c presenter. Please note that we DO NOT have copies of the slides that are shown during the conference.

Sachs Associates are delighted to welcome you to the:

3rd Annual

European Life Science CEOForum for Partnering & Investing11-12 February 2010ConventionPoint, Zurich, Switzerland

General Information• The registration desk is open from 8am on both days although you are welcome to join the event

at any time. Please collect a copy of the agenda for information on timing and room allocation for each session.

• Coffee stations are distributed around the foyer and the presentation rooms throughout the event. • Wireless Internet connection is available throughout the venue for the duration of the event. Please

ask for an access code at the registration desk.• The one-to-one meetings are being held in the Bid and Ask room. Please bring with you a copy of

your diary. Should you have any queries about your schedule, the laptop situated by the meeting tables is available for your assistance.

Sachs Associates are delighted to welcome you to the 3rd Annual European Life Science CEO Forum for Partnering & Investing. Following its success from previous years, the forum once again provides access to an exciting cross-section of venture-funded and small-cap companies with leading investors and pharmas.

This exclusive and transactional event complements our Annual Biotech in Europe Investor Forum, held later in the year, but with added focus on Partnering & the pharmaceutical industry, feature presentations from Big Pharma representatives demonstrating their current and future partnering strategies through thought-provoking case studies.

This year’s programme features a series of panels and presentations from leading investment, pharmaceutical and biotech companies, highlighting the current issues surrounding the evolving M&A market, Vaccines, Medtech Investment and includes special keynote speeches, providing an expert outlook on Europe’s Biotech industry. In addition, the event holds more than 50 company presentations from an exciting and diverse range of publicly listed and private life science companies, looking to raise fi nance and/or fi nd partners.

This year’s DyoDelta Life Science Innovation Awards takes place in the evening of the 11th February and the awards recognise exceptional performance in key categories of partnering and fi nancing within the industry..


AWARDS



WELCOM

ESPONSORS

WELCOM

E

back

Events Diary

10th AnnualBiotech In Europe Investor Forum29 - 30 September 2010 • Radisson Blu Hotel • Zurich Airport

Back for its 10th year, the Biotech in Europe Investor Forum will once again be held in Zurich, this year at the new venue, the Radisson Blu Hotel by Zurich Airport. Featuring our core sponsors, an audience of over 400 investors, analysts & media, with presenting opportunities for over 60 public and private companies and panel themes including Finance & Investment, Partnering and more, this event is a must for all key players in the Biotech and Pharma industry.

The forum will be an excellent platform for companies to raise their profi le by promoting their interests to the larger fi nancial community. Facilitated by its successful one-on-one meeting system and networking receptions, the event will help build strong and meaningful business relationships through face to face communication, and promises to be a great opportunity to meet emerging companies, leading global investors, analysts, advisors and Big Pharma representatives. Panel discussions with participation from industry leaders and experts in their sector, makes the Biotech In Europe Investor Forum an excellent way to gain insight and keep up to date with partnering and investment and current industry trends.

For regular updates, sponsorship, presenting and attending opportunities and further information regarding any of our future events please contact Rosa Lippard on [email protected]


AWARDS



WELCOM

ESPONSORSSPONSORS

next

Host Sponsor

www.six-swiss-exchange.com

Europe’s leading exchange for life sciences companies

Swiss fi nancial institutions manage more than one-quarter of the world’s offshore assets and represent the backbone of Switzerland’s strong fi nancial marketplace. As a result, companies listed on SIX Swiss Exchange achieve a high level of visibility within this fi nancially potent investor community.

In Switzerland, the life sciences industry in particular has developed over the past years into an internationally recognised and strongly emphasized sectoral focal point:

1. In Europe, SIX Swiss Exchange has grown to become the most important securities exchange in terms of the total market capitalisation of listed life sciences companies: 42% of Europe’s life sciences market capitalisation is attributable to the SIX Swiss Exchange.

2. Collectively, these representatives of the industry account for roughly one-third of the overall market capitalisation of the Swiss equity market.

3. Listed companies in the life sciences fi eld such as Novartis, Roche and Actelion engender an environment that exudes global charisma.

4. Differentiated sector-specifi c indicators such as the SXI LIFE SCIENCES® and SXI Bio+Medtech® indices, as well as the unusually broad analyst coverage of this particular sector, ensure transparency and outstanding visibility.

5. The SIX Swiss Exchange has seen the largest biotech IPOs in Europe in terms of money raised on the day of the IPO every year since 2004 and was the only regulated exchange who recently attracted European biotech crossborder-IPOs.

With a public offering of securities in Switzerland, and thanks to the tremendous placing power afforded by the Swiss-based investment banks, life science companies gain access to a sectorally experienced, highly competent and broadly international circle of investors.

Moreover, the location-specifi c advantages of Switzerland and favourable general conditions contribute to the attractiveness of an initial public offering on the SIX Swiss Exchange:

1. The Continental European marketplace with the most pronounced international orientation2. A leading fi nancial centre for equity-focused institutional investors3. A strong private banking industry with a broad investor base4. Multilingual and multicultural investors5. Focus on life sciences and small- and mid-caps6. Numerous banks with established in-house research departments7. Active bond and derivatives markets8. An attractive, market-oriented regulatory environment thanks to self-regulation9. Acceptance of various accounting standards (US-GAAP, IFRS, Swiss GAAP ARR and additional

internationally recognised standards)10. Low foreign exchange risk (listing in various currencies is possible)

Further information on the topic of IPOs on the SIX Swiss Exchange can be accessed at: www.six-swiss-exchange.com/download/about/div_pub/swx_ipoguide_en.pdf

Should you have further questions with regard to a public offering of securities, the various stock market segments or any other exchange-related topic, please feel free to contact our Issuer & Investor Relations team.

SIX Swiss ExchangeIssuer & Investor RelationsSelnaustrasse 30, Postfach, CH-8021 ZürichT +41(0)58 854 22 45 F +41(0)58 854 22 40


AWARDS



WELCOM

ESPONSORSSPONSORS

back :: next

Sponsors

www.dyodelta.com

DyoDelta Biosciences Ltd., is a London based company specialising in providing Business Development and Due Diligence support to companies and investors in the Pharma / Biotech sector.

DyoDelta Biosciences’ team averages more than 20 years experience per person and more than 150 years of cumulative experience. DyoDelta Biosciences has thousands of contacts at the senior corporate level worldwide and across the life sciences industry. The team’s executives have put together multiple types of deals, including R&D collaborations, strategic alliances, product licensing, acquisitions, disposals, fi nancings and local geography partnering, with NPVs adding to billions of dollars.

DyoDelta Biosciences covers Europe, the US and Japan, in guiding and supporting pharma and biotech companies, investors, institutions and organisations in corporate transactions, evaluation and due diligence.

Corporate deals with pharma companies are key to progressing development, providing funding, validation and also the trigger to investors for either an IPO or further funding.

DyoDelta Biosciences provides support to professional investors (funds) in the pharma and biotech sector the following areas:

• Market Research and Analysis• Identifi cation of suitable opportunities• Deal Sourcing• Industry Contacts• Commercial & Technical Evaluation• Due Diligence

For more information, please contact:Dimitri F. Dimitriou, M.Sc.Chief Executive Offi cerDyoDelta Biosciences LtdBerkeley Square HouseBerkeley SquareLondon W1J 6BDUK

Tel: +44 20 7396 5572Fax: +44 20 7396 5599

DyoDelta Biosciences


AWARDS



WELCOM

ESPONSORSSPONSORS

Sponsors back

www.serono.com

Our active ingredient is Innovation

At Merck Serono, we are actively committed to bringing therapeutic innovations to patients. We specialize in the treatment of cancer, neurodegenerative diseases, infertility, endocrine and metabolic disorders, cardiovascular diseases and other conditions with unmet medical needs.

Around the world, over 17,000 employees work to discover, develop, manufacture and commercialize Merck Serono’s prescription therapies, available in over 150 countries.

We are internationally recognized as a biotechnology leader, with innovative and successful products along with a well-stocked and promising development pipeline. Specialized know-how in research and production means that we are able to ensure absolutely high-quality manufacturing, a key success factor especially in the biopharmaceutical industry.

In 2007, sales of Merck Serono products generated total revenues of €4.5 billion. We devote 20% of these earnings to the pursuit of innovative new therapies through our own research and development, strategic alliances and agreement.

Merck Serono S.A.9, chemin des Mines Case postale 54 CH-1211 Geneva 20 Switzerland

Tel.: +41-22-414 3000Fax: +41-22-414 2179

Merck Serono International SA


AWARDS



WELCOM

ESPONSORS

SPEAKERS

Speakers

next

Dr Genghis Lloyd-Harris, Partner, Abingworth Management Ltd

Dr Genghis Lloyd-Harris, Partner joined Abingworth in 2004 from Credit Suisse First Boston (CSFB) where he was a Managing Director in the European Equity Research Group based in London. Genghis was responsible for coverage of the European biotechnology industry and was ranked fi rst for Pan-European Biotechnology in the Institutional Investor surveys each year from 2001 to 2003. Before joining Equity Research at CSFB, he worked for CSFB’s Health Care Group in the Investment Banking Division in New York. Genghis was previously a paediatrician in Melbourne, Australia. His current and past directorships have included HBI, Novexel, Solexa and Synosia Therapeutics. Genghis holds a Medical Degree from the University of Liverpool in the UK, a PhD in Clinical Pharmacology from the University of Melbourne, Australia, and an MBA from Harvard Business School. He focuses on exits of Abingworth’s venture investments via mergers and acquisitions and IPOs as well as venture investment in the UK and Continental Europe.

Simon Buckingham, President, Global Corporate and Business Development, Actelion Pharmaceuticals

Simon Buckingham is responsible for managing the future strategic direction of the company, reporting to the CEO. This role specifi cally involves leading and integrating the functions of Strategic Planning, Business Development and Portfolio Management. Before taking up this role in 2005, he was President of North America and Asia Pacifi c. He was responsible for Actelion’s sales, marketing, medical and regulatory activities in the US from the subsidiary‘s inception in South San Francisco in 2000. He has presided over the successful launch of Tracleer® in the US, Canada and Australia, as well as Zavesca® in the US. His experience in pharmaceutical sales, marketing and development spans around 20 years. He joined Actelion early in 2000 and, prior to that, held positions in sales, marketing and development at Parke-Davis US (1998-2000), the pharmaceutical division of Warner Lambert, and at Roche in both Switzerland and Australia (1990-1998).

Education: Veterinarian by trainingBachelor of Veterinary Science (Honours), University of Sydney, Australia (1984)Doctor of Philosophy, University of Melbourne, Australia (1988)Graduate Management Qualifi cation, Australian Graduate School of Management, University of New South Wales, Australia (1990).

Anders Hedegaard, President and CEO, Bavarian Nordic A/S

Mr. Hedegaard joined Bavarian Nordic A/S in August 2007. Prior to this he worked with the pharmaceutical company, ALK-Abelló A/S, where he was Executive Vice President, Business Operations & International Marketing and member of the executive management. His previous management career includes executive and management positions with FOSS A/S and Novo Nordisk A/S.

Mr. Hedegaard holds a M.Sc. degree in chemical engineering specialising in molecular biology.

Markus Hosang, General Partner, BioMedPartners

Dr. Markus Hosang is a General Partner at BioMedPartners AG in Basel, Switzerland. He has strong experience and broad knowledge in strategic and operational aspects of the venture capital business, as well as in pharmaceutical research and in many product development and marketing areas, with special expertise in the areas of biotechnologies, strategic alliances, and theranostics/diagnostics. Before joining BioMedPartners in 2004, Dr. Hosang was a Venture Partner at MPM Capital, where he was co-responsible for their European deal fl ow, and served on the boards of several European portfolio companies. Previously, he was at Roche in Basel, where, for nearly 20 years, he held several senior management positions in the Pharma R&D organization, including Vice President and Director of Global Pharma Research Strategic Unit and Chief of Staff to the President of Pharma R&D, membership of the Global Board of R&D Directors, Head of Development Projects in Basel and Member of the Roche Portfolio Board, and most recently, as a VP and CSO of Genetics and Integrated Medicine, and a member of the Roche Genetics Executive Committee.

He obtained his Ph.D. in Biochemistry from the ETH in Zurich and pursued his postgraduate training at Stanford University Medical School in neurobiology and subsequently at the University of Washington in Seattle. Dr. Hosang served on the Board of Directors and the Board of Trustees of the Swiss Foundation for Stipends in Medicine and Biology (SSMBS) as its Treasurer from 1994-2002. He currently is a member of the boards of Avontec GmbH, Okairos AG and Suppremol GmbH. Earlier he was on the boards of Omrix, Kourion (until its merger with ViaCell), IDEA and Atugen. He has published more than 30 articles in peer reviewed journals, and is coinventor on several patents.


AWARDS



WELCOM

ESPONSORS

SPEAKERS

back :: next

Speakers

Stephanie Léouzon, Senior Advisor, Investment Banking, Credit Suisse

Stephanie Léouzon is a Senior Advisor in Credit Suisse’s Investment Banking Division, focusing on European Health Care clients. She has worked in Health Care Investment Banking since 1989, participating in over 65 transactions in the biotechnology, pharmaceutical and speciality pharmaceutical sectors. She has advised clients on a number of strategic transactions, valued at over $70 billion, and she has been involved in fi nancing transactions to provide over $7 billion to healthcare clients.

Prior to joining Credit Suisse in 1998, Stephanie’s experience included working in Health Care at Lehman Brothers, JP Morgan and Salomon Brothers (now Citigroup). Stephanie earned an M.B.A. degree from the Darden Graduate School of Business at the University of Virginia in 1989 and a B.A. degree, cum laude, from Mount Holyoke College in 1985.

Dimitri F. Dimitriou, Chief Executive Offi cer, DyoDelta Biosciences

Mr. Dimitriou has over 20 years’ experience in the pharmaceutical and biotech industry. His past roles include Senior Director, Worldwide Business Development at GlaxoSmithKline, where his responsibilities included worldwide corporate deals with pharmaceutical and biotech companies. He held a similar role in Europe for Bristol-Myers Squibb. He is also the founder and Chief Executive Offi cer of ImmuPharma plc. He has a degree in biochemistry from the University of London (Kings College) and an MSc in pathology and toxicology from the Imperial College Medical School of the University of London.

Wolgang Renner, Chief Executive Offi cer, Cytos AG

Wolfgang A. Renner, PhD in biotechnology, has been heading the Company since its incorporation and has been Delegate of the Board of Directors and Chief Executive Offi cer of Cytos Biotechnology since July 1998. He obtained his PhD in 1995 from the Swiss Federal Institute of Technology (ETH), Zurich. It was his thesis that provided the basis for the foundation of Cytos Biotechnology GmbH in 1995. His achievements were honored with several awards, among them the “Swiss Economic Award”, the “Entrepreneur of the Year Award”, and the third prize of the “European BioTechnica Award of Excellence in Biotech Business. He is a member of the Committee of Science and Technology of the Swiss Federation of Commerce and Industry (Economiesuisse) and of the Foundation Council of the Swiss National Science Foundation.

Marion Jung, Principal, Earlybird Venture Capital

Marion Jung joined Earlybird in 1999 as an Associate and was promoted to Principal in 2002.

Since joining Earlybird, Marion has been involved in building Earlybird´s portfolio in the healthcare markets in Europe and the US. With her broad international network, Marion works closely with Earlybird´s portfolio companies to help them achieve their value-creating milestones as well as being involved from Earlybird’s initial investment through subsequent fi nancing rounds and exit. These companies include Amaxa AG (Cologne) which was sold to Lonza Group Ltd. (SWX: LONN), Wilex which listed on Prime Standard Frankfurt Exchange (WL6). and Dianoema S.p.A., which listed on the Borsa Italiana (Milan: NOE.MI). Marion focuses on innovative technologies deployed in the medical device and pharmaceutical industries as well as related technologies in cleantech.

Marion joined Earlybird after her postdoctoral training in molecular biology at the Ludwig-Maximilians-University in Munich. She earned her PhD under the supervision of Prof. Dr. Svante Pääbo while working on genetic peculiarities of mammalian mitochondria. She gained further research expertise in programs at Arizona State University in Phoenix, Arizona and at the Marine Biological Laboratory in Woods Hole, Massachusetts.

Marion received a Dipl.- Biol. (MS equivalent) from the Ludwig-Maximilians-University in Munich. She is the author of several articles that have been published in peer reviewed journals.


AWARDS



WELCOM

ESPONSORS

SPEAKERS

back :: next

Speakers

Eric Le Royer, CEO, Endosense

Eric Le Royer is a medical device industry professional with more than 20 years of leadership experience in global marketing, sales and business management. Since joining Endosense in 2005, he has led the development of a novel force sensing cardiac catheter, the TactiCath®. Prior to Endosense, Le Royer spent nearly 15 years at Guidant Corp., where he held various leadership positions on three continents. His most recent roles included vice president of marketing for Europe, general manager of the U.S. carotid and peripheral business unit, and director of the cardiac rhythm management unit in Japan. Le Royer received his engineering degree (diplôme d’ingénieur) from the Ecole Supérieure d’Electricité in France and a master’s degree in electrical engineering from the University of Houston. He also earned a master’s degree in business administration from Columbia University.

Matthew Walls, CEO, Epistem Plc

Matthew joined Epistem in April 2007 as Chief Executive Offi cer to guide the Company through admission to LSE:AIM. Epistem is one of the fastest growing Biotechnology Companies in Europe. Matthew is an experienced CEO, most recently with Oxford Biosignals Limited, where he led strategic collaborations with Rolls Royce Plc and Covance Inc. Matthew Spent the early part of his career with ICI Plc, progressing through to AstraZeneca Plc prior to its plant crop biotechnology group merger with Novartis AG to form Syngenta Plc. Matthew has led the growth of several technology and biotechnology companies as CEO, including Internexus Limited and Zylepsis Limited. He holds a non-executive post at Continum Limited and Riyada Oxford Investments Limited and is a Chartered Accountant and member of CIMA.

Arthur Franken, Partner, Gilde Healthcare Partners

Mr. Franken joined Gilde in 2001 as business analyst. In 2005 he was appointed investment manager. He has been involved in numerous transactions including Ablynx, Agendia, AMT, BG Medicine, IDEA, Neuro3D and Pieris. Mr. Franken led the investments in Conatus Pharmaceuticals, MTM Laboratories and FlowCardia.

Mr Franken represents Gilde on the boards of FlowCardia and MTM Laboratories.

Prior to joining Gilde Mr. Franken gained experience in cardiovascular research at TNO. He holds a masters degree in Biopharmaceutical Sciences from Leiden University. During his degree, Mr Franken specialized in molecular toxicology at the departments of Toxicology and Biopharmacy in the Leiden/Amsterdam Center for Drug Research. He is a Dutch national.

Shelagh Wilson, Vice President, Head of European CEEDD, GSK

Shelagh Wilson is Head of the European CEEDD, which focuses on setting up external alliances with world-class biotech companies throughout Europe and the emerging markets in Asia. She is one of the founding members of the CEEDD, having been appointed Head of Biology in June 2005. As a member of the CEEDD leadership team Shelagh helps set CEEDD strategy, sponsors CEEDD business deals for approval by GSK, and serves on multiple joint steering committees overseeing a drug discovery portfolio spanning diverse therapeutic areas.

Prior to joining the CEEDD Shelagh spent over 20 years in drug discovery, working in a variety of therapeutic areas including metabolic, CNS and cardiovascular disease areas. She also worked in the genomic arena, helping lead a transnational team responsible for identifying many novel G-protein coupled receptors from the human genome. The team successfully transitioned over 45 novel targets into the Drug Discovery portfolio across a range of therapeutic areas, several of which progressed into GSK’s development pipeline.

Shelagh graduated from Bristol University with a fi rst class honours degree in Biochemistry, subsequently taught chemistry and maths as a VSO volunteer in Ghana, and obtained her PhD from Chelsea College, London, studying cancer-induced cachexia. She is co-author on over 70 peer-reviewed scientifi c publications.


AWARDS



WELCOM

ESPONSORS

SPEAKERS

back :: next

Speakers

Carlton Brown, CEO, Immune Targeting Systems

Carlton is a veterinarian and holds an MBA from The London Business School. He has a commercial background in life sciences; strategic marketing (SmithKline Beecham), corporate and business development (Cortecs Plc) and global healthcare investment banking (Dresdner Kleinwort Wasserstein). Prior to ITS, he was Commercial Director and Chief Operating Offi cer of a French vaccine company. In October 2003 Carlton co-founded ITS and since then has successfully raised the Company’s Seed, Series-A and Series-A extension funding rounds and grant funding (£14m). He strategically directed the innovation and development of the vaccine platforms from inception to permit the targeting of mutating viruses whilst addressing key vaccine development imperatives. Carlton is particularly interested in developing products capable of addressing key market needs with a specifi c focus on market disruption.

Stan Yakatan, Chairman, Katan Associates

After 30 years as a successful CEO, entrepreneur, and operational manager, Stan Yakatan has dedicated the last 12 years of his career to sharing his experiences with management teams interested in building technology based companies. His experience as an executive is far reaching as he has served in an Executive capacity with:

• New England Nuclear • EI Dupont • CN Pharma • New Brunswick Scientifi c • Biosearch

These experiences have provided him with management skills and a corporate fi nance acumen that he enjoys sharing with others.

He has founded or co-founded in excess of 15 companies in the United States, Canada, Israel, France and Germany and in many cases served as the initial CEO, and Chairman of these companies. He currently sits on the board of directors of several public and private companies and has advised several of the world’s leading venture capital fi rms including TVM (Germany), Ventana (USA), MSP (USA) and Biocapital (Canada). During the decade of the 1990’s Biocapital was the most successful venture capital fund in Canada.

Stan currently serves in a business development capacity for the XL TechGroup. XL Tech Group systematically discovers unmet business needs, then creates, selects, and develops new technology businesses, and scales them to liquidity. Stan assisted XL TechGroup in the development of its business model, and advised on the overall capitalization strategy for XL Tech Group. In October 2004, XL TechGroup undertook an Initial Public Offering in connection with its listing on the Alternative Investment Market (“AIM”), raising in excess of $40.0 million.

Stan has completed and advised on numerous acquisitions and corporate fi nance transactions raising in excess of $1.0 billion dollars in the public and private capital fi nancing markets. He is a frequent speaker at fi nancial and biotechnology conferences throughout the world speaking on topics including, “Capital Raising for the Technology-Based Start-Up” and “The Need to be Global in the Quest for Capital and Partners”. Rick Biondi, Editor of Lab Business Magazine stated,” Mr. Yakatan is a venture capital raising Guru and it is part of his genetic make up.”

Stan is currently the Chairman of Grant Life Sciences, Inc. (OTCBB:GRTV) a company developing a revolutionary test for the screening of cervical cancer. He also serves as the strategic advisor to the state government of Victoria, Australia. Stan is the Executive Director and Chairman of Biocomm, in Melbourne, Australia, the fi rst of its kind regional business development agency and early-stage capital pool. Stan currently and sits on the Board of Mercury Therapeutics, Inc. which is developing new drugs for diabetes and obesity and Phenomenome Discoveries, Inc., a novel biomarker company.

Thomas Klaue, CFO, Medigene

Before joining MediGene, Dr. Klaue has been a partner at Fozzati Partners LLC, Frankfurt, a private investment bank where he acted as an advisor on business transactions for major fi nancial investors. Prior to that he was Vice President Business Development with Infi neon Technologies AG for more than fi ve years, where he held several senior management positions. He established the emerging biochip business, managed the strategic investment group and the corporate venture capital fund, and was head of M&A, organizational development, and cooperations in the US, Europe, and Asia. Prior to that he was Vice President M&A at DaimlerChrysler Aerospace AG, Munich (today’s EADS) for fi ve years. Before that, he was the Director and head of department for the pharmaceutical and chemical industry at the Treuhandanstalt, Berlin, the federal organization in charge of privatizing the east German Economy, where he gained four years of experience in reorganization and privatization. Dr. Klaue is a chemical engineer and holds a doctorate in business economics. He obtained his management education at the MIT Sloan School and as a Harvard Business School graduate in Boston, USA.


AWARDS



WELCOM

ESPONSORS

SPEAKERS

back :: next

Speakers

Anthony Hartley, Executive Director, Morgan Stanley

Dr Anthony Hartley is an Executive Director in the Healthcare Investment Banking Group at Morgan Stanley, where he focuses on pharmaceutical and biotechnology companies on a pan-European basis.

Anthony has spent 10 years in healthcare investment banking, predominantly focused on the European biotech and pharmaceutical sectors, and before joining Morgan Stanley previously worked for Lehman Brothers Europe and Credit Suisse First Boston.

He has completed and advised on numerous acquisitions and corporate fi nance transactions in both the public and private biotech sectors including advisory transactions for Addex Pharmaceuticals, AstraZeneca, Ark Therapeutics, BioXell, ESBATech, GPC Biotech, Jerini, ProStrakan, Protherics, Novartis, Q-Med, Serono and SkyePharma.

Anthony holds a Doctorate (D.Phil) in Pharmacology from The University of Oxford, and an MBA (Distinction) from Manchester Business School. Prior to his career in investment banking, Anthony spent a total of 7 years in the pharmaceutical industry working in a variety of research and commercial roles at Pfi zer, GlaxoSmithkline and AstraZeneca.

Roel Bulthuis, Head of Merck Serono Ventures, Merck Serono Ventures

Roel Bulthuis is Head of Merck Serono Ventures, the strategic venture capital group of Merck Serono. Through the ventures group, Merck Serono is committed to actively invest in emerging biotech companies which have the potential to provide innovative products in Merck Serono’s core therapeutic areas, or access to innovative technologies. In addition to the venture fund, Roel is also responsible for all ‘externalization’ transactions at Merck Serono, including ‘fostering’ deals, spin-offs and other alternative fi nancing models. Roel joined Merck Serono in 2006 and is based in Geneva, Switzerland. Previously, Roel was a Director in the Biotech Investment Banking Team at Fortis Bank, where he was responsible for the origination and execution of a wide range of fi nancing and strategic transactions in the biotech sector based out of Amsterdam and New York. Before joining Fortis Bank, Roel worked at Devgen NV in Gent, Belgium, as a business analyst. Roel holds a Msc. in Biopharmaceutical Sciences from Leiden University, the Netherlands, and an MBA in Finance from the Helsinki School of Economics, Finland.

Naveed Siddiqi, Partner, Nomura Phase4 Ventures

Naveed joined the Healthcare Corporate Finance Group at Nomura in 1998 and subsequently has focused on Phase4’s investment activities since 1999. Prior to joining the Team he gained several years experience advising management teams and companies on buy-outs, cross border M&A, private and public company offerings in biotechnology and other sectors whilst at Nomura and EFG Group.

He has over a decade’s experience as an investment professional with Phase4 Ventures and has been involved in numerous investments including Pharmion, Paratek, Phenomix and Altus Pharmaceuticals. Naveed holds a degree in Medicine from Guy’s Hospital, London and worked in the UK’s National Health Service as a doctor. He qualifi ed as a chartered accountant with KPMG and holds a Diploma in Company Direction from the Institute of Directors.

Esteban Pombo Villar, Head of Strategic Alliance Management EU, Novartis Institutes for BioMedical Research (NIBR)

Esteban Pombo-Villar PhD CChem FRSC is Head of Strategic Alliance Management at the Novartis Institutes for BioMedical Reasearch (NIBR) in Europe. The Strategic Alliances group is responsible for identifying, evaluating, negotiating and establishing research collaborations with academic and biopharmaceutical groups world-wide. Dr Pombo-Villar obtained his PhD in Organic Chemistry from the University of Warwick in the UK. After postdoctoral studies at the ETH in Zurich, he joined Sandoz Neuroscience Research in Basel in 1988, and worked on drug discovery projects as well as leading collaborative projects for investigation of emerging technologies. He was External Collaborations Manager for Neuroscience and from 2003, has been Head of Strategic Alliance Management at NIBR, and focuses on the management of the existing alliances in NIBR.


AWARDS



WELCOM

ESPONSORS

SPEAKERS

back :: next

Speakers

Riccardo Manetti, Global Head of Search and Evaluation, Business Development and Licensing, Novartis Vaccines and Diagnostics, Inc

Riccardo Manetti is the Global Head of Search and Evaluation, Business Development and Licensing, Novartis Vaccines and Diagnostics, Inc., a business unit of Novartis AG, with 2009 sales of $ 2.4 billion. The responsibilities of the group he is leading include screening for licensing and partnership opportunities in the vaccines fi eld, including full evaluation and eventual negotiation and execution of various typologies of agreements, ranging from collaboration and evaluation agreements to co-development and commercial license agreements. Typically, prospective partners range from academies to small and large biotech companies.

Riccardo Manetti joined Chiron Vaccines in 1998 as a Strategic Marketing Manager and started his career in Business Development in 2001 in the same company, before Novartis took over in 2006. Over his 9 years experience in Business Development, Riccardo has fi nalized in excess of 250 deals, including 30 commercial license agreements with international partners.

Riccardo Manetti earned his biology degree from University of Siena, Italy and hi Ph.D. from University of Padova, Italy.

Ulrick Spork, Managing Partner, Novo Equity Growth

Prior to joining Novo A/S, Ulrik Spork spent seven years within international marketing and business development in the life science area and almost ten years in Novo Nordisk A/S; from 1994 as Director of Corporate Development responsible for M&A activities and equity investments. He then led Novo’s venture activities at their initiation in 1999 and was Senior Partner until 2008, and co-responsible for building the more than 50 company strong venture portfolio in Novo. Ulrik has extensive international experience serving on boards of venture funded companies and is a former Chairman of the Danish Venture Capital Association. Ulrik holds a MSc in Engineering, and a BSc in International Economics.

Markus Werner, Director International Licensing, Business Development, Nycomed

Markus is German and has a track record of more than nine years in pharmaceutical business development. He held different positions within biotech, generic and innovative pharmaceutical companies where he was working on different kind of BD projects such as in- and out-licensing or M&A. The involved assets included products in the very early stage of drug development as well as clinical and marketed products.

He is now working in Nycomed’s business development group in Zürich as Director International Licensing. Nycomed is a mid-sized pharmaco with €3.5bn in revenues and a strong strategic focus on partnering. More recently he was responsible for the in-licensing of two global antibody products from Micromet and Immunomedics. These are now in phase 1 and 2 and are an example who the antibody drug format became established within Nycomed by mere licensing means.


AWARDS



WELCOM

ESPONSORS

SPEAKERS

back :: next

Speakers

Peter Honig, Managing Director, PH Regulatory Medical Affairs

Dr. Peter Honig is an experienced leader in the strategic and tactical aspects of drug and vaccine development with expertise in clinical pharmacology, clinical program and clinical trial design, compliance, medical product safety, and medical product regulation. He joined Merck Research Laboratories (MRL) in 2002 and had responsibilities for Global Regulatory Affairs and Operations, Global Pharmacovigilance, Clinical Risk Management and Safety Surveillance, Clinical and Nonclinical Quality Assurance, the Japan Clinical Development Organization, MRL Compliance, as well as Worldwide Over-the-Counter Development. He was also responsible for Medical and Regulatory Policy for MRL and also had extended periods of responsibility for Global Clinical Research Operations, Global Clinical Data Management, Safety Assessment (toxicology), the MRL Training Organization and the Merck Manuals and Index. He co-chaired the Late Development Review Committee (LDRC) which governs all decisions for investigational and marketed products beyond Phase 2b and chairs the Development Leadership Committee (DLC) which is comprised of all Senior Leadership in MRL Development and addresses issues of strategic importance to the organization. Dr. Honig’s involvement and leadership has been critical to many new product approvals during his tenure at Merck including Emend™ (aprepitant), Vytorin™ /Zetia™ (simvastatin/ezetimibe), Januvia™ (sitagliptin), Rotateq™ (rotavirus vaccine), Proquad™ (MMR-Varicella quadrivalent vaccine), Zostavax™ (shingles vaccine), Gardasil™ (HPV vaccine) and Isentress™ (raltegravir), Nulotan™/Preminent™ (losartan/losartan-HCTZ) in Japan, Tredaptive™ (ex-US) and a large number of global supplemental indications. One of his most noteworthy accomplishments at Merck was his leadership of the highest priority company initiative in 2006 and 2007 known as the “End to End”, or E2, initiative. Handpicked for the leadership role of E2, Dr. Honig, reported directly to the CEO and realigned the structure, governance, and operating processes across the entire company resulting in improved alignment and decision making across the major divisions and functional areas of Merck. These changes, approved by Merck’s Executive Committee, resulted in the current Merck & Co. operating model.

Prior to joining Merck, Dr. Honig founded and was the fi rst Director of the Offi ce of Drug Safety in the Food and Drug Administration’s (FDA) Center for Drug Evaluation and Research. Dr. Honig joined the Center for Drug Evaluation and Research (CDER) as a medical offi cer in the Division of Oncology and Pulmonary Drug Products in 1993 and held a supervisory position in the Offi ce of New Drugs. He authored or co-authorited numerous FDA Guidance documents and during his tenure at FDA and received numerous awards and citations.

He has served in various leadership roles in the American Society of Clinical Pharmacology and Therapeutics (ASCPT) including President, Vice President, Member of the Board of Directors, Chair of the section on Pharmacoepidemiology, Drug Safety and Outcomes Research. He has been the PhRMA representative to the International Conference on Harmonization (ICH) Steering Committee and since 2003 and is the current co-chair of the ICH Global Cooperation Group (GCG) whose mission it is to promote regulatory harmonization in non-ICH countries and regions.

He received his baccalaureate, medical and public health degrees from Columbia University in New York. He has postgraduate training and is board-certifi ed in internal medicine and clinical pharmacology and has authored numerous peer reviewed publications and book chapters. Dr. Honig retains a faculty appointment at the Uniformed Services University of the Health Sciences and is a current Associate Editor of Clinical Pharmacology and Therapeutics. He currently served as a pharmaceutical consultant and is managing director of Peter Honig Regulatory and Medical Advisors, LLC.


AWARDS



WELCOM

ESPONSORS

SPEAKERS

back :: next

Speakers

Fintan Walton, CEO, PharmaVentures Ltd

Dr Walton is a business services and media entrepreneur who through several businesses has generated over $50 million in revenues.

Dr Walton gained broad commercial experience whilst holding management positions at Bass and Celltech. In particular he was involved in contract research and licensing agreements with European, Japanese and US corporations.

Dr Walton co-founded CONNECT Pharma, a business focused on assisting pharmaceutical and biotechnology companies worldwide in all aspects of deal making including strategic alliances, Mergers & Acquisitions and equity fi nancing. In 1997 the business became PharmaVentures. His company has worked with clients on a global basis, delivering more than 400 assignments.

As a publisher, Dr Walton established CONNECT Pharma Reports, PharmaVentures Reports and PharmaDeals – a broad range of publications and databases serving the commercial and business aspects of the pharmaceutical and biotech sectors.

In 2006, Dr Walton established PharmaTelevision the world’s fi rst on-demand television channel dedicated to the life sciences and medical sectors. PharmaTelevision produces weekly interviews with key executives in the pharmaceutical industry including Merck, J&J, AstraZeneca, Roche and Bristol-Myers Squibb.

Today, PharmaVentures is a profi table business comprising over 35 individuals with a wealth of experience in the pharmaceutical, biotechnology and associated industries and scientists. Together the team’s experience offer an in-depth knowledge providing second-to-none support to our clients who are based 50% in the USA, 40% in the EU and 10% in Australia/New Zealand/Japan. In April 2008, PharmaVentures was the transactional advisor to The Dow Chemical Company for the sale of Dowpharma’s small molecules business to Dr Reddy’s in India.

Carole Nuechterlein, Head of Venture Funds, Roche Venture Funds

Carole Nuechterlein has headed the Roche Venture Fund since 2001. Prior to her current position, she worked in the pharmaceutical/biotech as an attorney for ten years. She joined Roche from SangStat in Fremont California where she was General Counsel. Carole began her career working at Skadden Arps Slate Meagher & Flom in the M&A group. From there, she worked at Syntex/Roche in Palo Alto, California focusing on M&A, research collaborations and licensing deals. She has a BA from Valparaiso University and a JD from University of Michigan. She serves as a board observer at Aileron, Alios, Ambit, Ambrx, Conatus, Envoy, Idaho Technology and Nereus. More information on the Roche Venture Fund can be found at www.venturefund.roche.com.

Antoine Papiernik, Managing Partner, Sofi nnova Partners

Antoine Papiernik is a Managing Partner and he invests in life sciences. He joined Sofi nnova Partners in 1997, and was previously with CDC-Innovation, the venture arm of the Caisse des Dépôts group. Since joining Sofi nnova Partners, Antoine has been an initial investor and active board member in public companies like Actelion, Addex, Orexo, NovusPharma and Movetis, which went public respectively on the Zürich stock exchange, the Stockholm stock exchange, the Milan Nuovo Mercato, and the Belgium Stock Exchange, in Cotherix (initially NASDAQ listed, then sold to Actelion), CoreValve (sold to Medtronic) and Fovea (sold to Sanofi Aventis). He has also invested in and is a board member of private companies CoAxia, EOS, Lectus, SpineVision and Stentys. Antoine has an MBA from the Wharton School of Business, University of Pennsylvania.


AWARDS



WELCOM

ESPONSORS

SPEAKERS

back :: next

Speakers

Alexandra Goll, Partner, TVM Capital

Dr. Alexandra Goll joined TVM Capital in early 1998, and has since been responsible for 10 TVM Capital life sciences investments. She was an initial investor in Actelion Ltd (Allschwil, Switzerland) and a Series B lead investor of Idenix Pharmaceuticals, Inc. (Cambridge, Massachusetts). Dr. Goll was a member of the Board of Directors of Idenix until the sale of 51% of the company to Novartis in May 2003.

Currently, Dr. Goll serves on the Board of Directors of Albireo (Gothenburg, Sweden), Biovertis AG (Vienna, Austria), Cerenis Therapeutics (Toulouse, France and Ann Arbor, MI) and Wilex AG (Munich, Germany). She also represents the interests of TVM Capital with Addex Pharmaceuticals SA (Geneva, Switzerland), Ark Therapeutics Ltd. (London, UK), EUSA Pharma Ltd. (Europe), GPC Biotech AG (Martinsried, Germany), MediGene AG (Martinsried) and Newron Pharmaceuticals SpA, (Bresso, Italy).

Prior to her affi liation with TVM Capital, Dr. Goll was the Global Business Leader for HIV and CMV, and was responsible for strategic marketing and business development for Virology at Roche Ltd. in Basel. She had been involved in clinical development and managing commercialization strategies of products such as Neupogen® (under an agreement with Amgen), Hivid®, Cymevene® and Valcyte®. Dr. Goll holds a degree in pharmacy from the Free University of Berlin, and wrote her doctoral dissertation in natural sciences at Philipps University of Marburg. She was also honored with a post-doctoral position supported by the Boehringer-Ingelheim Foundation for fundamental research in medicine.

Simon Turton, Managing Director Healthcare, Warburg Pincus LLC

Dr. Simon Turton was a Principal at Index Ventures in Geneva prior to joining Warburg Pincus in 2002. Previously, Dr. Turton worked for Servier, the French pharmaceutical company, where he managed Northern Asia operations in Tokyo and Paris. He also worked for a pharmaceutical strategic alliances consultancy where he was in charge of business development. Dr. Turton has an M.B.A. from INSEAD, which he attended as a Sainsbury Management Fellow in the Life Sciences, and a Ph.D. in Pharmacology from the University of London. He is a director of Archimedes Pharma, ProStrakan and Tornier.

Peter Llewellyn-Davies, CFO, Wilex AG

Peter Llewellyn-Davies has been the company’s Chief Financial Offi cer and member of the executive board since 1 September 2006. He has over 20 years’ experience in leading positions in medium-sized companies in the commercial as well as the fi nancial sector. Prior to joining the company, as proprietor of PLD Management Service, Munich, Mr. Llewellyn-Davies provided support and advice to small and medium-sized companies regarding management and fi nancing questions. Prior to that he was an executive director of Müller Dairy (UK) Ltd., the English subsidiary of the Unternehmensgruppe Theo Müller GmbH & Co. KG. From 1996 until 2003 he was employed as an executive director at Süd-Chemie AG, Munich, responsible for the areas of fi nance, controlling, accounting, taxes, M&A and risk management. Mr. Llewellyn-Davies read business management, banking, marketing and controlling in London (Great Britain), St. Gallen (Switzerland) and Munich, and has a certifi cate in business studies from the University of London (Great Britain).


AWARDS



WELCOM

ESPONSORS

SPEAKERS

back :: next

Chairs

Lorenza Castellón, Financial Analyst, Equity Development Ltd.

Lorenza Castellón is a health & biotech equity analyst at Equity Development Ltd. covering private & publicly listed SMEs companies in Europe and Australia. Prior to joining Equity Development in January 2005 she held similar roles at leading international investment organisations.

Equity Development brings together investors and companies by means of writing and distributing detailed research. We provide the markets with both facts and opinions along with fair valuations based upon diverse and appropriate metrics. Over the last decade our brand has become synonymous with quality objective research and we have built close links with institutions across the UK and Europe; like them we are fully regulated. Our team of analysts are FSA approved and boast a cumulative several hundred years of experience. Please visit www.equitydevelopment.co.uk for more details and examples of our work or contact our Senior Biotech analyst Lorenza Castellón has many years experience in the sector having worked for leading international investment organisations.

Dr Douglas Pretsell, Associate Partner, Life Sciences, and General Manager, Munich, College Hill

Douglas is an Associate Partner in the Life Sciences team heading up the Munich Offi ce. He has 10 years experience in life sciences communications and currently focuses on medical device and diagnostics clients in Europe as well as existing biotech clients. As General Manager of the Munich offi ce, Douglas also takes responsibility for growing College Hill’s reputation and client base within Continental Europe. He manages client communications programmes including trade and corporate public relations and marketing, for quoted and private company clients. His academic background includes a PhD in Neuropsychopharmacology from the University of Cambridge and he has also completed a post-doctoral fellowship at Edinburgh University.

Dr. Tomas Kahn, Director, Deutsche Bank AG

Dr. Tomas Kahn is Director of the Expert Team Life Sciences at Deutsche Bank AG in Germany. He joined Deutsche Bank in 1997 as Senior Scientifi c Manager of the same Team, dedicated to the banking coverage of Biotech, mid cap Pharmaceutical and Life Science Tools companies in a broad spectrum of fi nancial transactions. Prior to joining Deutsche Bank, he worked at the German Cancer Research Center in the team of the 2008 Nobel laureate Harald zur Hausen, and held a position of Visiting Associate Professor of Molecular Biology at the Universidad del Salvador in Buenos Aires, publishing 37 scientifi c papers in the fi elds of basic molecular genetics and patient related research. In parallel to his scientifi c activities in the fi elds of virology, oncology and epidemiology, he worked as an expert consultant regarding product liability issues for the law fi rm Shook, Hardy & Bacon (London). Before relocating to Germany with a Humboldt-Foundation fellowship, he worked in research related to infectious diseases and oncology, as well as in establishing a production facility for therapeutic biotech molecules at BioSidus, and in clinical trials for the development of a meningococcal vaccine for Behringwerke. Dr. Kahn obtained his M.S. and summa cum laude doctoral degree in Genetics and Microbiology at the University of Buenos Aires, Argentina.

Beth Jacobs, Managing Partner, Excellentia Global Partners

Beth Jacobs, Managing Partner, Excellentia Global Partners - a life science focused investment bank located in New York City. EGP works closely with companies around the world, in the biotech, med device, molecular diagnostics and pharma sectors to drive capital formation and partnering opportunities. EGP is focused on identifying pathways to success for early stage companies.


AWARDS



WELCOM

ESPONSORS

SPEAKERS

back :: next

Chairs

Claudio Werder, Founder, Werder Consulting

University degree in economics of the University of Zurich (lic.oec.publ., 1976). More than 30 years as a pharmaceutical and medical technology analyst at Bank Vontobel, Zurich. As of 1997 built up and led the Life Sciences Europe Team with 5 analysts, covering Pharmaceuticals, Biotechnology, Medical Technology and Specialty Chemicals. In 2007 founded Werder Consulting, providing consulting services to start-up companies in the fi eld of life sciences (e.g. business plans, fi nancial plans, strategic positioning).

.

Dr Paolo Bessieres, Founder & CEO, PharmaWave Ltd

Dr Paolo Bessieres, founder and CEO of PharmaWave Ltd, has more than 20 years experience in Japan and other key Asian markets.

During his career, he has fi nalized several transactions in Japan, South Korea, China, South East Asia and Australia. He has been involved in the founding and the development of a company in India, worked on a Joint-Venture in China and involved in several other corporate projects in the region.

He established a vast network of personal relationship with many executives in the region, many of whom are currently collaborating with PharmaWave.

Dr Bessières has also held posts at University of Rome, General Hospitals in Rome, Sigma-Tau Group, VSL International and he is currently the Vice President at ImmuPharma Plc.

Dr Bessières is a regular lecturer on issues related to the Japanese and Asian pharmaceutical markets.


AWARDS



WELCOM

ESPONSORS

SPEAKERS

back :: next

Pharma Partners

Guillaume Vignon, Associate Director Negotiation, Early Stage Licensing, Merck Serono

Guillaume Vignon is Associate Director Negotiation in the Early Stage Licensing department of Merck Serono. This group is currently responsible for identifying and structuring different types of partnerships around enabling technologies and pre-clinical stage assets which have a strategic fi t with Merck Serono’s core therapeutic areas. Guillaume joined the group Merck KGaA in 2006 as a Consultant in the Inhouse Consulting department where he conducted several assignments in the fi eld of strategy and management consulting, business development, commercial operations BU Oncology, and business planning. In 2008, Guillaume joined the Early Stage Licensing department of Merck Serono and relocated from Darmstadt, Germany, to Geneva, Switzerland, where he is still based now. Guillaume holds a Ph.D. in Molecular Biology and Biochemistry from the University Paris 6, France, and an MBA from the Hult International Business School in Cambridge, USA.

Margaret Beer, Senior Director and Head Licensing and External Research, Europe, Merck & Co

Margaret Beer studied at the University of Reading (Zoology) and at the University of London (Biochemistry) before carrying out her research work on serotonin pharmacology, leading to the award of her Ph.D, under the supervision of Prof. Derek Middlemiss. She joined Merck, as a neuroscientist, in 1984 following her return to the UK from Stanford University.

She is one of the founding members of the team responsible for the development of Merck’s anti-migraine drug MAXALT and was involved in the project during the basic research stage through to the launch in 1997. Her other main areas of research interest include depression, anxiety and multiple sclerosis.

Margaret joined the Worldwide Licensing and External Research, Europe, group, under the leadership of Dr Ray Hill, in 2003. This group was established in 2002 specifi cally in recognition of the scientifi c excellence in Europe and the wealth of potential licensing opportunities. Margaret assumed leadership of the group in 2008 following the retirement of Ray Hill.

She is the co-author of 100 original research articles, review articles, and abstracts, and has presented widely at international professional meetings.

Paul Leijten, Senior Partnering Director, Teva Pharmaceutical Industries LTD

Paul Leijten obtained his M.D. degree from the University of Amsterdam. He joined Bristol-Myers Squibb in 1986, after 5 years of academic research in cardiovascular pharmacology in the U.S. At BMS, he was involved in various aspects of drug development, including clinical pharmacology, clinical research; and in strategic planning and scientifi c licensing.

Since May 2008, he has been Senior Partnering Director at Teva Pharmaceutical Industries where his team leads the search for novel, early-stage compounds. In this role he has assessed multiple projects from academia, start-ups and mature biotech companies.

Teva Pharmaceuticals is an Israeli-based, global Top-20 Pharma company, with both generics and proprietary products on the market and in its pipeline. Teva aims to expand upon its previous focus on Israeli academic and company alliances to include globally-sourced partnerships in novel, proprietary medicines.

David Chiswell, CEO, Nabriva Therapeutics AG

David Chiswell joined Nabriva Therapeutics in March 2009 as Chief Executive Offi cer. After a career as a research scientist in both the UK and the US and nine years working in scientifi c management at Amersham International, David was co-founder of Cambridge Antibody Technology (CAT) in 1990. He was responsible for operational management from 1990 to 2002 including as CEO from 1996 to 2002. CAT listed on the London Stock exchange in April 1997 and Nasdaq in June 2001. Since leaving CAT in March 2002 David has been focusing on the development of early stage biotechnology companies including positions as non-executive Chairman of Sosei Ltd, Arrow Therapeutics Ltd, and Daniolabs Ltd and as a director of Arakis Ltd. David is currently Executive Chairman of Albireo Ltd and is an advisor to Nomura Phase IV ventures. David is a past Chairman of the UK’s BioIndustry association (BIA) and remains on their board. In 2006 he was awarded the OBE by HM Queen for services to the biotechnology industry.


AWARDS



WELCOM

ESPONSORS

next

Accera, Inc. www.accerapharma.com

CONTACTSDr Steve Orndorff Founder, President & CEO

Mr Eric SchaubleSenior Director, Corporate Development

ADDRESSAccera, Inc.380 Interlocken Crescent, Suite 780Broomfi eld, CO 80021USA

TELEPHONE(303) 999-3700

FAX(303) 999-3799

[email protected]@accerapharma.com

YEAR FOUNDED2001

FINANCIAL SUMMARY

Financing:$50M in venture fi nancing. Currently soliciting new investor(s) to fi ll out a pending Series D round of $20 M

Investors:Inventages Venture Capital • Posco Bioventures.

COMPANY PROFILE

Accera, Inc. is a privately held commercial-stage biotechnology company that discovers and develops breakthroughs in treating central nervous systems disorders. Accera developed and launched Axona® in the US for mild-to-moderate Alzheimer’s disease (AD) through our own sales force of 45 who detail to PCPs and neurologists. Accera engages in research, development and commercialization of other clinical applications for Axona, and has a wholly owned subsidiary, Neuera Pharmaceuticals, with a pipeline of small molecule drugs for neurodegenerative diseases.

TECHNOLOGY

Axona (Ketsyn/AC-1202) is a fi rst-in-class, breakthrough approach, for the treatment of Alzheimer’s disease (AD) and related neurodegenerative disorders. Axona is a prescription medical food for the clinical dietary management of the metabolic processes associated with mild-to-moderate Alzheimer’s disease. Axona addresses the hypometabolism or defective metabolism of glucose that occurs in those areas of the brain that are involved in Alzheimer’s disease and many other neurodegenerative diseases. Axona has been evaluated in three clinical trials for mild-to-moderate Alzheimer’s disease and Age Associated Memory Impairment. Axona has demonstrated signifi cant improvement in the gold standard measure of memory (ADAS-cog) on top of standard of care therapies and also demonstrated a strong pharmacogenomic response (7 pt improvement, p < 0.01 in APOE4- subjects) in clinical trials to date. Effi cacy demonstrated in the ApoE4(-) sub-population (50% of Alzheimer’s patients) was superior to the leading approved drugs for AD.

With simple oral administration, once-a-day convenience, and a superb safety profi le, Axona is complementary to current Alzheimer’s disease therapies and ideal for chronic administration. For more information about Axona, please visit www.about-axona.com

Accera holds worldwide rights to Axona and is currently seeking partners for ex-US development and commercialization for Axona. We are also seeking license, co-promote or distribution rights to commercial CNS drugs for our existing sales force.

MANAGEMENT Senior Management:Dr Steve Orndorff, Founder, President, & CEOMr William Poncy, VP, Commercial DevelopmentDr Samuel Henderson, VP, ResearchMr Greg Kading, VP, Finance

Board of Directors:Claude H. Nash, Ph.D., ChairmanGary HooperSteve Orndorff, Ph.DWolfgang Reichenberger, Ph.D.Gunnar Weikert, M.D., Ph.D., MBAThomas Werner, Ph.D.


AWARDS



WELCOM

ESPONSORS

back :: next

Addex Pharmaceuticals Ltd. www.addexpharma.com

CONTACTMr Chris MaggosInvestor Relations & Communications

ADDRESSAddex Pharmaceuticals Ltd12 Chemin des Aulx1228 Plan-les-OuatesGeneva Switzerland

TELEPHONE+41 22 884 1555

FAX+41 22 884 1556

[email protected]

YEAR FOUNDED2002

FINANCIAL SUMMARY

Shares in Addex trade on the SIX Swiss Exchange main board under the stock symbol ADXN (ISIN: CH0029850754). There were 5,862,492 ADXN shares outstanding as of June 30, 2009. Addex had CHF94.5 million in cash as of June 30, 2009 and can fund operations through end of 2011.

COMPANY PROFILE

Addex Pharmaceuticals utilizes its unique proprietary platform technologies to discover and develop allosteric modulators for human health. Allosteric modulators are a different kind of orally available small molecule therapeutic agent, which we believe will offer a competitive advantage over classical drugs. The Addex pipeline demonstrates the productivity and broad potential of this unparalleled platform. The most advanced product, ADX48621 mGluR5 negative allosteric modulator (NAM), has completed early clinical testing and is scheduled to start mid-stage clinical testing in the fourth quarter of 2010 for treatment of Parkinson’s disease levodopa induced dyskinesia.

Our platform technologies already have proven their value through our relationships with four of the top 10 pharmaceutical companies in the world. Specifi cally, under an agreement with Ortho-McNeil-Janssen Inc., a Johnson & Johnson company, ADX71149, an mGluR2 positive allosteric modulator (PAM), is undergoing Phase I clinical testing and has potential for treatment of schizophrenia and anxiety. Under two separate agreements with Merck & Co., Inc., we are developing PAMs of mGluR4 and mGluR5 as drugs to treat Parkinson’s disease and schizophrenia, respectively. In addition, SR-One, the corporate venture arm of GlaxoSmithKline, and Roche Venture Fund have made signifi cant investments in Addex.

TECHNOLOGY

Addex has built a unique chemical library and proprietary high-throughput screening tools to discover and develop allosteric modulators, a class of drug-like molecules that were diffi cult to identify. Most drugs must out-compete endogenous ligands for the active site. By contrast, allosteric modulators are non-competitive because they bind receptors and generally only modify their function when the endogenous ligand also binds. Allosteric modulators aren’t limited to simply turning a receptor on or off, the way most drugs are. Instead, they act more like a dimmer switch, offering control over the degree of activation or deactivation, while allowing the body to retain control over initiating receptor activation. This mechanism presents unique discovery challenges, many of which Addex has overcome.

MANAGEMENT Senior ManagementVincent Mutel, Chief Executive Offi cerTim Dyer, Chief Financial Offi cerCharlotte Keywood, Chief Medical Offi cerSonia Poli, Head of Non-Clinical DevelopmentEmmanuel Le Poul, Head of CNS Business UnitLaurent Galibert, Head of Infl ammation Business UnitJean-Philippe Rocher, Head of Core ChemistryRobert Lütjens, Head of Core BiologyChris Maggos, Investor Relations & Communications

Board of Directors/Affi liationAndré J. Mueller, ChairmanAndrew Galazka, SVP Scientifi c Affairs, Merck-Serono Ray Hill, former Head of EU Licensing, Merck & Co., Inc.Vincent Lawton, former MD of Merck Sharp & Dohme U.K. and VP of MSD EU Beat E. Lüthi, CEO of CTC AnalyticsVincent Mutel, Vice Chairman & CEO of AddexAntoine Papiernik, Sofi nnova Partners


AWARDS



WELCOM

ESPONSORS

back :: next

Affectis Pharmaceuticals AG www.affectis.com

CONTACTMr Alex MartinChief Executive Offi cer

ADDRESSAffectis Pharmaceuticals AGFraunhoferstrasse 1382152 MartinsriedGermany

TELEPHONE+49 89 8932811 100

FAX+49 89 8932811 111

[email protected]

YEAR FOUNDED2004

COMPANY PROFILE

Affectis is a biopharmaceutical company developing novel drugs for the treatment of psychiatric and neuroinfl ammatory disorders.

Affectis’ unique capabilities in drug discovery and behavioural pharmacology allow the company to develop drugs with innovative mechanisms of action based on pioneering fi ndings.

Today’s psychiatric market is dominated by therapeutic concepts that are decades old. Shortcomings of existing drugs range from delayed onset of action to a signifi cant rate of non-responders and unwanted side effects. Affectis’ programs carry the promise of bringing to market entirely new classes of drugs that would address and satisfy unmet needs.

MANAGEMENT

Management TeamHerbert Stadler, CEOAlex Martin, CFOLuc St-Onge, CBOMichael Bös, CSOInge Sillaber, Behavioural Pharmacology Marcelo Paez-Pereda, Discovery

Board of DirectorsJoachim Rothe, ChairmanDomenico Valerio, Vice-ChairmanStefan HerrWolfgang Wurst

Scientifi c Advisory BoardHanns Möhler, ChairmanFlorian Holsboer, PsychiatryKay Brune, PharmacologyFrancesco DiVirgilio, Infl ammationKlaus Wanner, ChemistryAdriaan Sitsen, Clinical trials


AWARDS



WELCOM

ESPONSORS

back :: next

ALRISE Biosystems GmbH www.alrise.de

CONTACTSDr Celal AlbayrakChief Executive Offi cer

Dr Volker Rindler Director BD

ADDRESSALRISE Biosystems GmbHRobert-Roessle-Str. 1013125 BerlinGermany

TELEPHONE+49 30 9489 2483

FAX+49 30 9489 2482

[email protected]@[email protected]

YEAR FOUNDED2004

FINANCIAL SUMMARY

Alrise is privately held and was funded by two VC companies and one private investor.

Group Investors: IBB Beteiligungsgesellschaft Berlin mbH and VC Fonds Berlin GmbH • Creathor Venture • Private Investor – Dr Giuseppe Vita.

COMPANY PROFILE

ALRISE Biosystems GmbH develops controlled-release formulations for protein, peptide and small molecule drugs. The cornerstone of ALRISE’s business is its patented parenteral drug delivery technology ImSus® for the encapsulation of active pharmaceutical ingredients in biodegradable polymeric nano or microparticles. However, ALRISE not only offers a unique technology, but also provides a platform from which products can be developed to meet the ever increasing needs of pharma, biotech, and generics drug companies. ALRISE’s mission is to make its innovative encapsulation technology available to a broader user spectrum and ultimately to create benefi t for patients worldwide.

TECHNOLOGY

ALRISE’s technology platform ImSus® is a unique world-wide patented parenteral drug delivery technology for the design and manufacture of drug-loaded polymeric nano and microparticle formulations. It allows an effi cient encapsulation of drugs nearly independent of molecule size and chemical properties. Controlled-release depot formulations, as manufactured with ImSus® technology, help reducing the dosing frequencies, minimizing the fl uctuation of drug concentration in serum, and may reduce adverse side effects by generating more favourable pharmacological profi les.

Key advantages of the ImSus® technology include its use of non-toxic solvents, its simple one step process, comparatively small process scale, short manufacturing time, homogenous product morphology, low initial burst and high encapsulation effi ciency.

MANAGEMENT Senior ManagementDr Celal Albayrak, Chief Executive Offi cerDr Volker Rindler, Director BDDr Heiko Seemann, Director Formulation Dev.

Scientifi c Advisory BoardDr Giuseppe VitaDr Alessandro BanchiProf Dr Hans-Peter MerkleProf Dr Roland Bodmeier


AWARDS



WELCOM

ESPONSORS

back :: next

AM-Pharma www.am-pharma.com

CONTACTMr Bart WuurmanChief Executive Offi cer

ADDRESSAM-PharmaRumpsterweg 63981 AK BunnikThe Netherlands

TELEPHONE+31 30 228 9222

FAX+31 30 228 9220

[email protected]

YEAR FOUNDED2002

FINANCIAL SUMMARY

€25 million Euro invested so far.Financing activities ongoing with aim to raise €17 million to achieve an exit in 2013.A €5m Dutch government loan was granted in 2009.

Major investors: Forbion • Inventages.

COMPANY PROFILE

AM-Pharma has shown clinical Proof of Concept for treatment of Acute Kidney Injury with bovine Alkaline Phosphatase (bAP) in two separate Phase II trials.

Clinical Proof of Concept was also shown for treatment of severe Ulcerative Colitis in a Phase II trial with orally administered bAP.

Motivated by these positive results AM-Pharma is now raising money to fi nance a switch to its proprietary recombinant human Alkaline Phosphatase (recAP) for further development in Acute Kidney Injury.

Once recAP has shown to be safe and effective in Phase II, we intend to fi nd a Pharma partner for further development and worldwide marketing.

PRODUCTS

Recombinant Alkaline Phosphatase

With Phase IIa clinical proof of concept in: – Acute Renal Failure (iv) – Ulcerative Colitis (oral)

MANAGEMENT

Dr Bart Wuurman, CEODr Jacques Arend, CMODr Erik van den Berg, CBODr Steve Connor, CPOPeter Verwayen, CFO

Non-Executive BoardEric Claassen, ChairmanBart Bergstein, ForbionBogdan von Rueckmann, InventagesDavid Brister, independentFrank Morich, independent


AWARDS



WELCOM

ESPONSORS

back :: next

Archimedes Pharma Ltd. www.archimedespharma.com

CONTACTSMr Tim WattsInterim Chief Operating Offi cer & Chief Financial Offi cer

Mr Michael ClarkChief Commercial Offi cer

ADDRESS250 South Oak WayGreen ParkReadingRG2 6UGUnited Kingdom

TELEPHONE+44 (0)118 931 5050

FAX+44 (0)118 931 5051

EMAILTimWatts @archimedespharma.commichaelclark @archimedespharma.com

YEAR FOUNDED2004

FINANCIAL SUMMARY

Archimedes is a privately held company backed by management and Warbug Pincus, a leading private equity investor with extensive experience in the healthcare sector.

In 2009, Archimedes had sales of £22.5 million.

COMPANY PROFILE

Archimedes is a European specialty pharmaceutical company with an established commercial organisation in the UK, France, Germany, Ireland and Spain.

Archimedes is developing a robust pipeline of innovative near term products to support its commercial organisation. Archimedes’ lead product is NasalFent®, a fentanyl nasal spray for rapid relief of breakthrough cancer pain utilising the Company’s proprietary PecSys™ delivery technology. NasalFent® has successfully completed global Phase III clinical trials and has been fi led for regulatory approval in the EU and the USA.

Archimedes’ products include Gliadel, a biodegrable wafer impregnated with carmustine for high grade glioma; Zomorph, an oral sustained release morphine product for cancer pain; Oramorph, an immediate release liquid morphine product for moderate to severe pain; Apomorphine Injection for motor fl uctuations in advanced Parkinson’s disease; Pabrinex, a high potency formulation of vitamins B and C for alcohol misuse; and Zibor, a second generation low molecular weight heparin for thromboprophylaxis.

Archimedes’ strategy is to grow its commercial presence organically, through the acquisition of marketed brands in Europe and through partnering or licensing of European rights to new specialist prescribed products.

Archimedes has an established development organisation with proprietary technologies for nasal and oral drug delivery and a number of products in development. These capabilities and technologies are also offered to pharmaceutical companies on a fee-for-service or licensing basis.

TECHNOLOGY

Archimedes’ versatile and innovative technologies underpin in-house drug development and a number of partnered products in late stage development:

ChiSys® – a proprietary chitosan-based nasal drug delivery technology that facilitates the delivery of small polar drugs, peptides, proteins and vaccines.

PecSys™ – a proprietary pectin-based system for delivery of drugs to mucosal surfaces, especially the nasal cavity, modulating absorption.

TARGIT® – an enteric polymer-coated starch capsule to deliver bioactive materials to the lower GI tract.

MANAGEMENT

Tim Watts, Interim Chief Operating Offi cer & Chief Financial Offi cerMichael Clark, Chief Commercial Offi cerCharles Marchetti, Group Corporate Development DirectorAlan Smith, Vice-President, Research & Development


AWARDS



WELCOM

ESPONSORS

back :: next

Axentis Pharma AG www.axentispharma.com

CONTACTDr Helmut BrunarCEO

ADDRESSAxentis Pharma AGLimmatquai 138CH-8001 ZurichSwitzerland

TELEPHONE+41 44 202 7878

FAX+41 44 287 2400(@ Klein Attorneys at Law)

[email protected]

YEAR FOUNDED2007

FINANCIAL SUMMARY

Axentis Pharma has raised approximately 2 million EURO during the past six months from equity investors and has a current share capitalization of 1.700.000 shares.

COMPANY PROFILE

Axentis Pharma is a Swiss-based respiratory specialty pharmaceutical company focused on applying novel formulations and drug delivery technologies to known drug compounds. Founded in 2007, Axentis Pharma’s main asset is a clinical phase II treatment for cystic fi brosis with launch date planned for 2012.

TECHNOLOGY

Axentis Pharma’s lead product is a clinical phase II treatment for cystic fi brosis. This product, a patented liposomal formulation of tobramycin named Axentis TOBRA® (Fluidosome® tobramycin or ARB-CF0223), is an inhalable treatment for patients suffering from cystic fi brosis with chronic Pseudomonas infection. The Axentis formulation is expected to have a dosing advantage and possibly improved effi cacy.

The company’s proprietary liposomal platform is also Axentis’ value driver for targeting the COPD / Bronchiectasis indication midterm.

Axentis owns world wide (except Japan and Korea) development and marketing rights to the technology through an exclusive licensing agreement with aRigen, Inc., Japan.

MANAGEMENT Senior ManagementDr Helmut Brunar, PhD, CEODr Susanne Acklin, PhD, COODr Madhu Davies, MD, Clinical PlansMrs Sue Green, Regulatory Affairs

Board of DirectorsDr Helmut Brunar, PhD, PresidentMr Stefan Wiesli, LL.M. MemberMr John Dawson, Member (designated)

Scientifi c Advisory BoardProf Hans Schreier, PhDProf Gergely Lukacs, MD, PhD


AWARDS



WELCOM

ESPONSORS

back :: next

Bavarian Nordicwww.bavarian-nordic.com

CONTACTMr Anders Hedegaard President & CEO

ADDRESSHejreskovvej 10A3490 KvistgaardDENMARK

TELEPHONE+45 33268383

FAX+45 33268380

[email protected]@bavarian-nordic.com

YEAR FOUNDED1994

COMPANY PROFILE

Bavarian Nordic is an industrial biotechnology company developing and producing novel vaccines for the treatment and prevention of life-threatening diseases with a signifi cant unmet medical need. The Group’s business strategy is focused in three areas: biodefence, cancer and infectious diseases, and includes seven development programmes. Two programmes are ready for Phase III: IMVAMUNE®, a third-generation smallpox vaccine is being developed under a contract with the US authorities, and PROSTVAC™, a therapeutic vaccine for advanced prostate cancer is being developed under a collaboration agreement with the National Cancer Institute, USA (NCI).

Bavarian Nordic’s patented technology, MVA-BN®, is as demonstrated in clinical studies, one of the most safe, multivalent vaccine vectors for the development of vaccines against various infectious diseases such as smallpox, HIV, as well as against breast and prostate cancer.

Bavarian Nordic has two high-technology production facilities. One of the facilities, located in Kvistgaard in Denmark, is designed for the commercial production of IMVAMUNE® and MVA-BN® recombinant vaccines. Located in Berlin, Germany, the other facility is designed for the production of recombinant vaccines for clinical research. Bavarian Nordic also has a fi lling and packing contract with IDT Biologika in Dessau, Germany.

With operations in Denmark, Germany, the USA, and Singapore, Bavarian Nordic employs over 365 people.


AWARDS



WELCOM

ESPONSORS

back :: next

BioCeramic Therapeutics Limitedwww.bioceramictherapeutics.com

CONTACTIan Brown, MBA FAICD FAIM Managing Director & CEOMobile: +44 (0) 7540 687 457

ADDRESSBioCeramic Therapeutics LimitedImperial IncubatorLevel 2, Bessemer Building (RSM)Exhibition Road, London SW7 2AZUnited Kingdom

TELEPHONE+44 (0)20 7594 1326

[email protected]

YEAR FOUNDED2007

FINANCIAL SUMMARY

Series A round planned for 2010.

COMPANY PROFILE

BioCeramic Therapeutics Limited is a company which has been spun out of Imperial College London with pipeline agreements and collaborations with the leading academics at Imperial’s Department of Materials.

TECHNOLOGY

BioCeramic Therapeutics Limited is focused on medical device products manufactured with advanced materials to support and enhance natural cellular growth and tissue regeneration in-vivo. The materials are composed of bioactive ceramics in a granular, dense or porous, powder or paste format, or biomimetic fi brous scaffolds for three-dimensional tissue in-growth. A major BioCeramic Therapeutics Limited material science innovation is the use of strontium, boosting the performance of the ceramics.

Advanced materials to support and enhance natural cellular growth and tissue regeneration in-vivo

BioCeramic Therapeutics Limited has also applied unique innovative approaches in generating its fi brous scaffolds so that the materials contain key components that interact at the cellular level and produce signals enabling faster and more effective tissue regeneration.

BioCeramic Therapeutics Limited is commercialising its technology portfolio in the fi eld of bone and soft-tissue regeneration materials, specifi cally bioactive ceramics (with strontium) and bioactive scaffolds for tissue in-growth.

KEY ADVANTAGES

Enhanced cellular growth propertiesEnhanced anti-bacterial properties

PORTFOLIO OF PATENTS

The company has extensive patent coverage and freedom to operate in this fi eld. BioCeramic Therapeutics Limited has eight patent applications in its portfolio which have been fi led via the PCT route.

MANAGEMENT

Stephan Rietiker, ChairmanIan Brown, CEOMolly Stevens, CSODaniel Green, DirectorMark Rowan, DirectorJohn Holden, DirectorRon Petersen, Director


AWARDS



WELCOM

ESPONSORS

back :: next

Biotie Therapies Corp. www.biotie.com

CONTACTSDr Timo VeromaaPresident and CEO

Dr Thomas TaapkenChief Financial Offi cer

ADDRESSBiotie Therapies Corp.Tykistökatu 6FI-20520 TurkuFinland

TELEPHONE+358 2 274 89 00

FAX+358 2 274 89 10

[email protected]@biotie.com

YEAR FOUNDED2002

FINANCIAL SUMMARY

Listed on NASDAQ OMX Helsinki Ltd (BTHV1)Market cap: EUR 98.4 million Cash position Q3-2009: EUR 16.7 million

COMPANY PROFILE

Biotie is a drug discovery and development company focused on central nervous system and infl ammatory diseases. It has a broad range of innovative small molecule and biological drug candidates at different stages of clinical and pre-clinical development. Biotie’s products address diseases with high unmet medical need and signifi cant market potential, including addiction and psychotic disorders, rheumatoid arthritis, psoriasis and chronic obstructive pulmonary disease (COPD). The most advanced product, nalmefene for alcohol dependence, is currently in phase III clinical development by licensing partner H. Lundbeck A/S.

The commercial value of the pipeline has been demonstrated through existing alliances with top-tier global pharmaceutical companies such as Lundbeck, Roche and Pfi zer. Biotie has operations in Turku, Finland and Radebeul, Germany.

TECHNOLOGY

Nalmefene is currently in phase III development for the treatment of alcohol addiction disorders and is already licensed to Lundbeck.

Two compounds targeting infl ammatory disorders are also in clinical development:

• ELB353 is an orally available PDE4 inhibitor with potential application in several infl ammatory indications and has completed one phase I clinical study, a clinical pharmacology study with biomarkers is ongoing;

• Biotie recently reported that it has successfully completed a clinical trial with its fully human VAP-1 monoclonal antibody (BTT-1023) in rheumatoid arthritis patients.

The study evaluated the safety, tolerability, and pharmacokinetics of repeated doses of intravenously administered antibody in 24 rheumatoid arthritis patients with an inadequate treatment response to methotrexate. The antibody, administered at repeated doses of up to 8 mg/kg in combination with methotrexate, was generally well tolerated, and no serious or severe adverse events were reported in the study subjects. The pharmacokinetic characteristics of BTT-1023 are consistent with those expected for an intravenously administered monoclonal antibody intended for chronic conditions.

The pipeline has been endorsed by leading international pharmaceutical partners such as Pfi zer, Roche, and Lundbeck.

MANAGEMENT

Management Team Dr Timo Veromaa, President & EODr Thomas Taapken, CFODr Antero Kallio, CMO Dr Thomas Kronbach, CSOMr Chris Piggott, CBO

Board of DirectorsMr Juha Jouhki, ChairmanMr Pauli MattilaDr Riku RautsolaMr Piet SerrureDr Ann HanhamDr Bernd KastlerDr Christoph Schröder Dr Peter Fellner


AWARDS



WELCOM

ESPONSORS

back :: next

BruCells SA www.brucells.com

CONTACTDr Gilles CapartManaging Director

ADDRESSBruCells SARue de Ransbeek 310B-1120, BrusselsBelgium

TELEPHONE+32 2 263 07 00

FAX+32 2 263 07 09

[email protected]

YEAR FOUNDED2001

FINANCIAL SUMMARY

Raised so far 4.3 million Euros in 4 equity rounds plus 4.7 million Euros in research grants.Looking for 15+ million Euros equity to complete development of fi rst two products. Series A venture capital, partnership or IPO are currently being considered.

COMPANY PROFILE

BruCells SA has developed a unique concept of cancer drug with wide therapeutic applications. The concept belongs to the new class of immunotherapies (cancer vaccines), which can be combined with existing and new reference treatments. The safety profi le and the medical plausibility based on investigational clinical trials are excellent.

The Company intends to demonstrate the concept in exploratory clinical trials on kidney (RCC) and brain (glioma) cancer, two unmet therapeutic needs, under orphan drug designation. The concept can be extended later to more prevalent indications in partnership with larger pharmaceutical companies.

The market potential for this concept is very large. Therapeutic vaccines, if effective, can substantially reduce the risk of relapse for most patients treated with reference therapies. The preferred setting at early stage in combination with reference treatments will also allow for faster market introduction.

TECHNOLOGY

The products are based on the patented concept of fusion vaccines, which combine the superior antigen presentation capability of dendritic cells with the wide spectrum of tumour associated antigens present in cancer cells. The production is based on unique proprietary cell lines, avoiding the limitations of autologous concepts and allows production on inventory.

MANAGEMENT

Senior ManagementGilles Capart, Ph.D.

Board of Directors/Affi liationJean Marie Delwart, Biotec SA, ChairBruno De Vuyst, BI3Jean Van Nieuwenborg, TheodorusSandrine Evrard, SRIBPierre Chatelain, Chemcom

Scientifi c Advisory BoardProf Ada Kruisbeek/VUmc, ChairProf Ulrich Zimmermann, Würzburg Univ.Prof Sadamu Homma, Jikei UniversityDr Gerd Johnscher, Pharmakon


AWARDS



WELCOM

ESPONSORS

back :: next

Capstone Therapeutics www.capstonethx.com

CONTACTMr Dana B. Shinbaum Vice President,Business Development

ADDRESSCapstone Therapeutics(tradename of OrthoLogic Corp.)1275 West Washington StreetSuite 101Tempe, AZ 85281USA

TELEPHONE+(602) 286 5520

FAX+(480) 452 1174

[email protected]

YEAR FOUNDED1987

FINANCIAL SUMMARY

US$38.7MM cash (30-Sep-2009)No long-term debtNASDAQ: CAPS52-wk Range: US$0.35 - $1.04

COMPANY PROFILE

Capstone Therapeutics (trade name of OrthoLogic Corp.) is a biotechnology company committed to developing a pipeline of novel therapeutic peptides aimed at helping patients with under-served medical conditions. The Company is focused on development and commercialization of two product platforms: AZX100 and Chrysalin® (rusalatide acetate or TP508).

AZX100 is a novel synthetic 24-amino acid peptide, one of a new class of compounds in the fi eld of smooth muscle relaxation and fi brosis. Based on its demonstrated effects in pre-clinical models and safety in clinical trials, AZX100 is currently being evaluated for commercially signifi cant medical applications such as the prevention or reduction of hypertrophic and keloid scarring, treatment of pulmonary disease and intimal hyperplasia. Capstone has an exclusive worldwide license to AZX100.

Chrysalin, the Company’s novel synthetic 23-amino acid peptide, has been proven in multiple pre-clinical and clinical models to stimulate cellular events leading to angiogenesis, revascularization, and repair of dermal and musculoskeletal tissues. It is currently being evaluated in disorders that involve vascular endothelial dysfunction, such as acute myocardial infarction and chronic myocardial ischemia. The Company owns exclusive worldwide rights to Chrysalin.

Capstone’s corporate headquarters are in Tempe, Arizona, USA. For more information, please visit the Company’s website: www.capstonethx.com.

MANAGEMENT

Senior ManagementJohn M. (Jock) Holliman, III, Executive ChairmanRandolph C. Steer, MD, Ph.D., President & COOLes M. Taeger, Senior Vice President & CFODana B. Shinbaum, Vice President, Business Development

Board of DirectorsFrederic J. Feldman, Ph.D., President of FJF Associates, a consultant to health care venture capital and emerging companiesJohn M. (Jock) Holliman, IIIElwood D. Howse, Jr. Founder, Cable, Howse and Ragen investment banking and stock brokerage fi rm, now owned by Wells Fargo

and known as Ragen MacKenzieWilliam M. Wardell, MD, Ph.D., Owner, Wardell Associates International LLC - consulting fi rm specializing in drug development, regulatory

approval, and safetyAugustus A. White, III, MD, Ph.D., Professor of Medical Education and Professor of Orthopedic Surgery, Harvard Medical School

Scientifi c Advisory BoardMichael E. Mendelsohn, MD, FACC., Chief Scientifi c Offi cer, Tufts Medical CenterCharles A. Dinarello, MD, Professor of Medicine, University of Colorado School of Medicine, Denver


AWARDS



WELCOM

ESPONSORS

back :: next

Celonic AG www.celonic.com

CONTACTDr Andreas Herrmann Chief Executive Offi cer

ADDRESSCelonic AGEulerstrasse 554051 BaselSwitzerland

TELEPHONE+41 615 649 150

FAX+41 615 649 169

[email protected]

YEAR FOUNDED2006

FINANCIAL SUMMARY

Celonic is a profi table Contract Manufacturing Organization having its own pipeline of innovative biopharmaceutical compounds.

Celonic has raised €9.1m within a seed fi nancing and Series A fi nancing round for the development of its therapeutic compounds.

COMPANY PROFILE

Celonic owns a therapeutic pipeline of biopharmaceuticals compounds for the treatment of widespread diseases, namely oncology and infl ammation. Two products are in late preclinical development for the treatment of immune system disorders such as rheumatoid arthritis, Crohn’s disease, psoriasis and infl ammatory bowel disease. The third product is dedicated to treat skin cancer, heaptocelluar carcinoma and head-and-neck cancer. All of Celonic’s products have successfully demonstrated proof of concept, are expected to be safe and well tolerated and are scheduled to enter the clinic end of 2010 and mid/end of 2011 respectively.

Besides, Celonic is a leading contract manufacturing organisation with strong expertise in mammalian cell culture technology. Celonic provides biopharmaceutical companies worldwide with services focusing on process development and GMP production of active pharmaceutical ingredients for clinical studies and market supply.

TECHNOLOGY

Celonic’s roots are in mammalian cell culture technology. Thus, the company has developed and patented methods for quick and regulatory compliant cell-line development (CEMAX®) and process development that enable the company to have a lead over its competitors and to offer excellent services for customers’ benefi t.

Celonic’s patent portfolio provides ample freedom to operate, consisting of 14 patent families, 48 fi led applications, thereof nine issued patents.

MANAGEMENT

Dr Andreas Herrmann, CEO and PresidentDr Stefan Stroissnig, VP Clinical DevelopmentDr Eric Guenzi, VP Preclinical DevelopmentDr Thomas Hassler, Head Quality AssuranceDr Karlheinz Landauer, Director R&D


AWARDS



WELCOM

ESPONSORS

back :: next

CerMed Corporation www.CerMedCorp.com

CONTACTSMr Peter Gombrich Chief Executive Offi cer

Ms Linda MastersonPresident and COO

Mr Stephen AmbrichChief Financial Offi cer

ADDRESSCerMed Corporation2511 Garden Rd., B100Monterey, CA 93940 USA

TELEPHONE+1-831-920-2275

FAX+1-831-920-2276


YEAR FOUNDED2007

FINANCIAL SUMMARY

Private CompanyCurrently Raising Private Placement of $1.5 MillionPlan Public Offering in 4-5 Months of $3 Million.

COMPANY PROFILE

CerMed Corporation, www.cermedcorp.com, is a privately owned international women’s healthcare company. CerMed is committed to improving the health of women worldwide by developing, manufacturing and marketing quality, high-value added medical products to prevent, diagnose and treat female reproductive system diseases. The Company focuses on two major markets: the cervical cancer screening market, an $18 billion market opportunity, and the market for a women’s controlled HIV contraceptive, a $52 billion market opportunity. CerMed is commercializing three innovative products which address signifi cant limitations of currently available methods in these huge markets. CerMed’s cervical cancer screening products provide the fi rst and only collection system that maps the location of identifi ed pre-cancerous cells – available this summer. In late stage development is the fi rst point-of-care system, non laboratory based HPV primary screening system to ultimately replace the commonly used, buy inaccurate, PAP smear. Additionally, CerMed is developing and testing the fi rst woman controlled contraceptive that will also reduce the risk of HIV – available in about 10 months.

TECHNOLOGY

CerMed has a strong technology and patent position through its own efforts as well as through in-licensed technology and OEM product development agreements. In total, CerMed products will be protected by at least 11 patents: 4 patents issued, 4 patents pending, and 3 under preparation.

MANAGEMENT

Peter Gombrich, CEO/Chair Raised over $200M, took 3 companies public. Founder St Jude Medical, ClinCom, and Acumed/Molecular Diag. Linda Masterson, Pres/COO Raised over $65M as CEO/Chairman public company LifePoint, instrumental in 4 prior successful start-ups Stephen Ambler, CA (UK) CFO Taken company public; extensive public and private fi nance exper.Paul Vichi, Ph.D., CSO 15 yrs exper. in mol biol. & nanotech – based technologies.Philip Darney, MD, MSc, SAB & Medical Director Chief, OB/GYN UCSF; Assoc Editor Contraception; Consultant to numerous countries; 300+ pubsRandal Cohen, MD, MPD, SAB. Lead investigator most African HIV studies; Director Fogarty Intl Cntr, Kenya; Prof OB/GYN UCSF;

Hundreds of Pubs.


AWARDS



WELCOM

ESPONSORS

back :: next

Clinuvel Pharmaceuticals Ltd. www.clinuvel.com

CONTACTSDr Philippe Wolgen Chief Executive Offi cer

Mr Darren KeamyChief Financial Offi cer

Mrs Daniela SchaeferHead of Business Operations Europe

ADDRESSClinuvel Pharmaceuticals LtdLevel 11, 330 Collins StreetMelbourne VIC 3000Australia

TELEPHONE+41 44 253 7500

FAX+41 44 253 7501

[email protected]

YEAR FOUNDED2001

FINANCIAL SUMMARY

ASX (CUV) listed in 2001Xetra/Dax (UR9)US ADR (CLVLY)

COMPANY PROFILE

Clinuvel is Australia’s photoprotective company. A leading and innovative company, Clinuvel is focused on the development of afamelanotide, its proprietary fi rst-in-class photoprotective drug. The company is headquartered in Melbourne with an operational offi ce in Zürich and, shortly, in New Jersey. Clinuvel is publicly listed in Australia (ASX: CUV), with a secondary listing in Germany (Xetra: UR9) and a Level 1 ADR in the USA (CLVLY).

The company is currently funded with USD$32M in reserves (Sept ‘09), suffi cient to develop afamelanotide to market for several indications. Its share-register is stable and diversifi ed over various Australian and leading European institutions.

Afamelanotide was granted dual orphan drug designation in Europe, the US and Switzerland for the treatment of 2 UV and light related skin diseases – porphyria (EPP) and solar urticaria (SU). Clinuvel has identifi ed in total 5 categories of patients who benefi t from medicinal photoprotection.

RECENT DEVELOPMENTS

• Promising preliminary results released from lead Phase III porphyria (EPP) trial• Positive results released from Phase II trial in photodynamic therapy • FDA granted afamelanotide second ODD, for solar urticaria (SU)• EMEA granted Clinuvel Small and Medium Enterprise (SME) status• Preliminary results released from Phase III trial in polymorphic light eruption (PLE)

TECHNOLOGY

Afamelanotide is a fi rst-in-line therapeutic being developed by Clinuvel. An analogue of -MSH, afamelanotide is a linear peptide which activates the skin to activate and produce eumelanin, the dark pigment which is known to have photoprotective properties (providing skin protection against light and UV radiation). Increased pigmentation of the skin appears a few days after administration of afamelanotide and lasts up to 60 days. Afamelanotide is administered underneath the skin as a dissolvable implant approximately the size of a grain of rice.

The drug formulation appears most effective in skin diseases exacerbated by UV and visible light (>400 nm wavelengths). From Phase II, and preliminary Phase III trial results published in January and December ‘09, effi cacy and safety was demonstrated. In 100 patients, reduction of severity and prevention of symptoms caused by UV and light of higher wavelengths was demonstrated.

Clinuvel is coming to the end of Phase III trials in the orphan designation porphyria (EPP) in Australia and Europe, with a US program submitted. The other indications are currently at Phase II or preparatory Phase III stage. An open label Phase II trial in Solar Urticaria (IgE allergy) showed effi cacy in all 5 patients subjected to clinical testing, whereby minimal urticarial dose (MUD) was signifi cantly increased (p< 0.001).

Clinuvel anticipates full results from its lead Phase III study – erythropoietic protoporphyria (EPP) – in Europe and Australia by Q1 2010..

Continued...


AWARDS



WELCOM

ESPONSORS

back :: next

Clinuvel AG www.clinuvel.com

CONTACTSDr Philippe Wolgen Chief Executive Offi cer

Mr Darren KeamyChief Financial Offi cer

Mrs Daniela SchaeferHead of Business Operations Europe

ADDRESSClinuvel Pharmaceuticals LtdLevel 11, 330 Collins StreetMelbourne VIC 3000Australia

TELEPHONE+41 44 253 7500

FAX+41 44 253 7501

[email protected]

YEAR FOUNDED2001

...continued

PRODUCTS / PROGRAMS

NAME INDICATION DESCRIPTION STATUS

Afamelanotide Erythropoietic Absolute sun/ Phase III trial preliminary Protoporphyria (EPP) UV intolerance results reported December 2009. Confi rmatory Phase III trial approved August 2009.

Solar Urticaria (SU) Acute anaphylactic Phase II trial results reaction to sun/UV reported July 2009

Photodynamic Therapy Phototoxicity following Phase II trial results (PDT) – systemic cancer treatment reported December 2009

Actinic Keratosis (AK)/ Skin cancer in transplant Phase II trial started and Squamous Cell patients October 2007 Carcinoma (SCC) in Organ Transplant Recipients (OTRs)

Polymorphous Light Severe sun/UV poisoning Phase III trial preliminary Eruption (PLE/PMLE) results reported December 2009

MANAGEMENT

Senior ManagementDr Philippe Wolgen, MD, CEODr Helmer Agersborg, CSODr Dennis Wright, VP Scientifi c AffairsMr Darren Keamy, CFO

Board of DirectorsDr Philippe Wolgen, MD, CEOMrs Brenda Shanahan, Non-Executive ChairDr Helmer Agersborg, Deputy Chair, CSODr Roger Aston, Non-Executive DirectorMr Stanley McLeish, Non-Executive DirectorMr Jack Wood, Non-Executive Director


AWARDS



WELCOM

ESPONSORS

back :: next

CONTACTSMr Mauro Ajani Chief Executive Offi cer

Dr Chris Tanner Chief Finance Offi cer and Head of Investor Relations

ADDRESSCosmo Pharmaceuticals SpA1 Cristoforo Colombo20020 LainateItaly

TELEPHONE+39 02 9333 7614

FAX+39 02 9333 7663

EMAILchris.tanner @cosmopharmaceuticals.com

YEAR FOUNDED1996

FINANCIAL SUMMARY

Listed on SIX.

COMPANY PROFILE

Cosmo aims to become a leading gastroenterology company. The present focus is on IBD specifi cally Ulcerative Colitis. Strategy is fi nd off patent chemicals entities that can be re-patented using the company’s patented MMX technology. The company has two products in the market and two in phase III, both licensed out for the US and EU markets and two phase II products that have not yet been licensed out.

TECHNOLOGY

The MMX technology is a targeted, delayed release technology for the delivery of chemical entities including proteins and peptides to the colon.

MANAGEMENT

Mauro Ajani, Majority shareholder and CEORolf Stahel, ChairmanGiuseppe Cipriano, COOLuigi Moro, CSO

Cosmo Pharmaceuticals www.cosmopharmaceuticals.com


AWARDS



WELCOM

ESPONSORS

back :: next

Diamyd Medical AB www.diamyd.com

CONTACTElisabeth LindnerCEO and President

ADDRESSDiamyd Medical ABKarlavägen 108SE-115 26StockholmSweden

TELEPHONE+46 (0)8 661 00 26

FAX+46 (0)8 661 63 68

[email protected]

YEAR FOUNDED1996

FINANCIAL SUMMARY

Diamyd Medical is a public company traded on the Nasdaq OMX Nordic Market Small Cap list (ticker: DIAM B) in Stockholm and on OTCQX in the US (ticker: DMYDY), with a market cap of approx SEK 3,500 million.

In October 2009 Diamyd Medical raised SEK 220 million in a new share issue. The additional capital is planned to last until the second half of 2011 with the current development program and to cover with margin the costs that the Company anticipates incurring until data from the current Phase III program is expected to be available. Since its inception in 1996 Diamyd Medical has raised approximately SEK 680 million. The company is fully equity fi nanced.

COMPANY PROFILE

Diamyd Medical is a Swedish biopharmaceutical company focusing on the development of pharmaceuticals for the treatment of autoimmune diabetes and its complications. Diamyd has three clinical-phase products. The company’s most advanced project is the diabetes vaccine Diamyd® for type 1 diabetes. The purpose of Diamyd® is to prevent, delay, or stop the autoimmune attack on beta cells in type 1 diabetes, thereby preserving the body’s capacity to regulate blood sugar. Phase III trials for this drug are in progress in both Europe and the US and results are expected in the spring of 2011. In addition, the company has initiated clinical studies in the US in the area of chronic pain, using its Nerve Targeting Drug Delivery System (NTDDS).

Diamyd Medical has offi ces in Sweden and in the US. Further information is available on the company’s website: www.diamyd.com.

TECHNOLOGY

Diamyd Medical develops therapies from two independent technological platforms in the areas of diabetes and diabetes-related complications. One of the platforms originates from the GAD65 molecule and is the basis for the Diamyd® diabetes vaccine, while the second platform NTDDS (Nerve Targeting Drug Delivery System), utilizes gene therapy to deliver medication directly to nerve cells. As a result of the cumulative research efforts, Diamyd Medical possesses a portfolio of three clinical-stage candidate drugs: Diamyd® for type 1 diabetes (Phase III), Diamyd® for LADA (Phase II) and the NTDDS product NP2 for chronic pain (Phase I). All three products are offered for licensing in selected markets.

MANAGEMENT

Elisabeth Lindner, President and CEODarren Wolfe, CEO of Diamyd Inc. USAErika Hillborg, Director of Clinical DevelopmentPeter Zerhouni, Director of Business DevelopmentNatalie Jelveh, Director of Business Control


AWARDS



WELCOM

ESPONSORS

back :: next

Emotional Brain B.V. www.emotionalbrain.nl

CONTACTSDr J.J.A. TuitenChief Executive Offi cer

Dr Joy Barton Business Development

Mr F.H.C. NijsChief Operational Offi cer

ADDRESSEmotional Brain B.V.Louis Armstrongweg 78Almere, 1311 RLNetherlands

TELEPHONE+31 (0) 36 5468346

FAX+31 (0) 36 5497186

[email protected]@emotionalbrain.nl

YEAR FOUNDED1999

FINANCIAL SUMMARY

Emotional Brain is a privately held company headquarterd in Almere.

COMPANY PROFILE

Headquartered in Almere NL, Emotional Brain’s research and clinical development programs focus on female sexual dysfunction (FSD). Its two most advanced products, Lybrido and Lybridos have completed an exploratory phase 2 clinical program. A confi rmatory clinical program to support registration is now underway and a commercial partner is sought for phase 3 and commercialization.

Independent sources estimate Female Sexual Dysfunction affects up to 40% of women of all ages, and various sources estimate the market size for an effective FSD drug to be upwards of US$5 billion. Lybrido and Lybridos are unique in that they target all the major types of FSD.

Emotional Brain’s early pipeline also focuses on FSD, and its subsidiary companies and business units develop innovative products for individualized healthcare.

TECHNOLOGY

Phase 2 small molecule programme to treat Female Sexual Dysfunction.

MANAGEMENT

Dr Adriaan Tuiten, CEOFrank Nijs, COO


AWARDS



WELCOM

ESPONSORS

back :: next

Epistem www.epistem.co.uk

CONTACTSMatthew WallsChief Executive Offi cer

John RylandsChief Finance Offi cer

ADDRESSEpistem Plc48 Grafton StreetManchester M13 9XX

TELEPHONE+44 (0) 7887 501998+44 (0) 161 606 7244

FAX+44 (0) 161 606 7348

[email protected]@epistem.co.uk

YEAR FOUNDED2000 – by Prof Chris Potten and Dr Cath Booth as a spinout from The Paterson Institute for Cancer Research in Manchester UK.

FINANCIAL SUMMARY

Listed on AIM (London) in 2007 at 124p.Further shares were placed in November 2007 and 2009.

Investors include: Helium, Generali, Gartmore, Octopus and Legal & General.

COMPANY PROFILE

Led by CEO, Matthew Walls, Epistem is a leading UK bio-technology company, which is commercialising its ex-pertise in epithelial stem cells in the areas of oncology, gastrointestinal diseases, dermatology and ageing. Based by Manchester University and with a US offi ce in Boston, Epistem works with most of the major international pharma companies and operates under three divisions:

• Contract Research Services providing specialised pre-clinical effi cacy testing; • Biomarkers developing an innovative minimally invasive plucked hair biomarker test for drug development

companies; and• Novel Therapies collaborating with Novartis to discover key regulators of epithelial cells and developing

therapeutics to control cell production, initially targeting oncology and infl ammatory bowel disease.

MANAGEMENT

Senior Management & Executive DirectorsMatthew Walls, CEOJohn Rylands, CFODr C Booth, CRODr J Moore, Novel TherapiesDr G Brady, Biomarkers

Non-executive DirectorsDavid Evans, ChairmanBob NolanRoger LloydProf Chris Potten

Scientifi c Advisory BoardProf Chris PottenProf Andrew HughesProf Tom Kirkwood


AWARDS



WELCOM

ESPONSORS

back :: next

Galantos Pharma GmbH www.galantos.com

CONTACTSDr Andreas KoepkeChief Business Offi cer, Managing Director

Prof Dr Alfred MaelickeChief Scientifi c Offi cer, Managing Director

ADDRESSGALANTOS PHARMA GmbHFreiligrathstrasse 12D-55131 Mainz Germany

TELEPHONE+49 6131 1440 311

FAX+49 6131 1440 329

[email protected]

YEAR FOUNDED2005

FINANCIAL SUMMARY

During the A-fi nancing round (750.000 €) Galantos Pharma received funds from the HTGF and FIB/ISB to reach “in vitro proof of concept” until June 2007. The B-fi nancing round (2,8 Mio. €) was lead by Dr. F. Yadegardjam, EVP, managing the VRP fund together with KfW, HTGF and ISB providing funds for preclinical development. The clinical candidate Memogain® was selected in March 2008, the optimal route of administration was established in October 2009, the fi nal formulation is currently developed for an IND / IMPD in Q3 2010. Currently, an internal C-fi nancing round (2.7 M€) is fi nalized to develop Memogain® until proof of concept in man after Phase Ib.

• Semi virtual development with burn rate <1 M€ p.a. so far• Total of 6.8 M€ secured• Within one year to clinical phase 1• Out-licensing attempted after clinical PoC• Two years to clinical phase 2• 500.000 k€ to 5 M€ desired until out-licensing

COMPANY PROFILE

Galantos Pharma GmbH thrives to become a leading company for the development of drugs for brain diseases, focussing on Alzheimer’s Dementia (AD). Its is located in the bioincubator “An der Goldgrube” in Mainz. The company founded by Profs. Alfred Maelicke and Ulrich Jordis, who have participated in the development of Galantamine for AD, which is marketed since 2000, one of the top 3 AD medications, summarized under the term “cholinesterase inhibitors”, serving a total market of 5 B USD per year. Galantos has improved the natural compound galantamine to improve potency and dramatically reduce peripheral side effects. We have created an unusually focused network of experts facilitating this breakthrough for the development of next generation AD therapy: Prof. Maelicke (founder, CSO) discovered the new mechanism of action (MoA) of galantamine, Prof. Jordis (co-founder) developed the patented total synthesis of galantamine, Dr. Köpke (CBO, Managing Director) used to work for Johnson & Johnson and coordinated the Maelicke collaboration on galantamine. Dr. Kaletta (MBA), with ten years of experience in the biotech industry, has recently become Head of Research and Development.

See: www.galantos.com

TECHNOLOGY

Galantos Pharma’s most advanced candidate is Memogain® for Alzheimer’s dementia. This NCE is a prodrug of galantamine (Reminyl®, Razadyne®) with:

• No peripheral side effects • Higher effi cacy at lower doses

GLP-Tox of Memogain® is fi nalized to result in an IND by Q3 2010. The clinical development is designed together with Dr. Remy Luthringer, CEO, Forenap, to result in PoC in phase 1b, within one year.

With its experience Galantos is well furnished to optimize further compounds for CNS targeting in collaborations. We are constantly expanding our technology platform of nicotinic receptor panels, neuroprotection and behavioral assays to optimize a selective €7 allosteric modulator. This new program recently received a government grant (BMBF) commitment of up to 2.3 M€.

.


AWARDS



WELCOM

ESPONSORS

back :: next

Glycotope GmbH www.glycotype.com

CONTACTSMr Steffen Goletz Chief Executive Offi cer

Mr Franzpeter Bracht Chief Finance Offi cer

Mr Georg Adelberger Business Development Manager

ADDRESSGlycotope GmbHRobert-Roessle-Str. 10 Berlin, 13125Germany

TELEPHONE+49 30 9489 2604

FAX+49 30 9489 2604

[email protected]@glycotope.com

YEAR FOUNDED2001

FINANCIAL SUMMARY

– Jossa Arznei GmbH– Eckert Wagniskapital und Frühphasenfi nanzierung GmbH

COMPANY PROFILE

Glycotope is a leading biopharmaceutical company in the fi elds of Glycomics and Immunotherapeutics. The company was founded in 2001 in Berlin, Germany and together with it’s subsidiary Glycotope-Biotechnology (Heidelberg, Germany) has currently more than 120 employees.

Glycotope´s pipeline consists of both novel and improved glycooptimized antibodies and a glycooptimized hormone, the 1st of which has recently entered clinical trial phase I.

Raising EUR 40 Mio. in 2007, Glycotope has completed one of the largest fi nancing rounds in European Biotech history and is funded to complete several Phase IIa studies until 2012.

TECHNOLOGY

With GlycoExpress, for our knowledge the only approved Glycooptimization technology that is not limited to antibodies, Glycotope engages in the development and enhancement of both proprietary and 3rd parties NBEs and 2nd generation proteins.

GlycoExpress consists of a set of human cell-lines that mediate targeted alteration of glycosylation constituents such as Fucosylation, Sialylation, Branching or Antennarity, resulting in a signifi cant improvement of bioactivity, -availability or immunogenicity.

Glycotope´s lead antibody GT-MAB 2.5-GEX for the treatment of cancer has just initiated clinical stage I. Targeting a novel carbohydrate epitope, the antibody combines an extremely high tumor-specifi city with high activity.

The 2nd of currently 5 pipeline projects, GT-MAB 5.2-GEX, further demonstrates the potential of infl uencing glycosylation. In comparison to the original Cetuximab, the 2nd generation antibody exhibits a drastically improved ADCC, providing the entire patient spectrum with availability for treatment, next to a signifi cantly elongated half-life time and a reduced immunogenicity based on the fully human glycosylation provided by GlycoExpress.

A further two antibodies and one glycooptimized protein hormone will enter the clinical stage successively within the next 18 months.

MANAGEMENT

Dr Steffen Goletz, CEO/CSODr Franzpeter Bracht, CFO/CBODr Hans Baumeister, COO


AWARDS



WELCOM

ESPONSORS

back :: next

immatics biotechnologies GmbH www.immatics.com

CONTACTSMr Paul Higham Chief Executive Offi cer

Ms Bettina Kipp Director & Head of Business Development

ADDRESSimmatics biotechnologies GmbHPaul-Ehrlich-Straße 1572076 TuebingenGermany

TELEPHONE+49 7071 5397-0

FAX+49 7071 5397-900

[email protected]@immatics.com

YEAR FOUNDED2000

FINANCIAL SUMMARY

2004/2005: € 14 mn Series A2007: € 40 mn Series B

Investors: DH Capital/ OH Beteiligungen (Dietmar Hopp) • Wellington Partners • 3i Group • EMBL Ventures • Grazia Equity • Merifi n Capital • Seed/L-Bank • Vinci Capital/Renaissance • The National Technology Enterprises Company (NTEC) • KfW

COMPANY PROFILE

immatics is a biopharmaceutical company dedicated to the development of innovative cancer immunotherapeutics.

immatics’ proprietary technology for the identifi cation of tumor-associated peptides (TUMAPs) enables the development of novel anti-cancer vaccines for multiple cancer indications. immatics is currently developing two multi-TUMAP products in clinical phase II studies – IMA901 for the treatment of renal cell carcinoma (RCC - study results will be available in January 2010) and IMA910 for the treatment of colorectal carcinoma (CRC). A third product, IMA950, for the treatment of malignant glioma (braincancer) is expected to enter development in early 2010. Further product candidates are currently in pre-clinical development. immatics was founded in 2000 as a spin-off from the Institute of Immunology at the University of Tuebingen (Prof. Hans-Georg Rammensee) and is based in Tuebingen and in Munich, both in Germany.

TECHNOLOGY

XPRESIDENT™ is a unique platform combining mass spectrometry, genomics, biochemistry, and immunology. Unlike other technologies, it is able to identify tumor-associated peptides (TUMAPs) directly from primary human tumor material, so that TUMAPs are confi rmed to be naturally processed and presented on real tumors removed by the surgeon and discarded otherwise.

XPRESIDENT™ enables the detection of TUMAPs down to a femtomolar level - a so far unrivalled sensitivity level. The technology is able to identify several thousand TUMAPs per year and selects the most immunogenic antigens through a proprietary T-cell validation platform. The platform is scalable and can be applied to many different oncology indications.

MANAGEMENT

Mr Paul Higham, Chief Executive Offi cerDr Carsten Reinhardt, Chief Medical Offi cerDr Harpreet Singh, Chief Scientifi c Offi cer


AWARDS



WELCOM

ESPONSORS

back :: next

Immune Targeting Systems www.its-innovation.co.uk

CONTACTSCarlton Brown Chief Executive Offi cer

Ken Powell Chairman

ADDRESSImmune Targeting Systems Ltd London BioScience Innovation Centre2 Royal College StreetLondon NW1 0NHUK

TELEPHONEOffi ce: +44 20 7691 4908Carlton mobile: +44 7970 944 454

[email protected]@googlemail.com

YEAR FOUNDED2004

FINANCIAL SUMMARY

Key investors: Novartis Venture Fund • HealthCap • Truffl e Capital • London Technology Fund.

Series-A: £4.5m (+£0.5m grant) June 2007

Series-A extension to close 05/02/2010: £8.65m. This round permits new investor post-closing on the same terms.

COMPANY PROFILE

Immune Targeting Systems is a London based biotech company developing synthetic vaccines for mutating viruses underpinned by its DepoVaccine and High Density Antigen identifi cation technology platforms.

ITS’s lead program is a synthetic universal infl uenza vaccine targeting all potential seasonal and pandemic fl u strains. Phase-I is expected to commence in Q3-2010 and pharmtox studies with GMP vaccine are in progress.

TECHNOLOGY

This next generation broadly applicable T-cell vaccine platform encompasses the DepoVaccine and High Density Antigen identifi cation technology platforms. DepoVaccines deliver high density antigens to the immune system and promote a vaccine depot at the injection site. This depot promotes potent, durable and recallable antiviral T-cell immunity without adjuvants.

Vaccine design specifi cally address key aspects of human immunological-vaccine performance required for clinical success; (i) vaccine responder frequency >95%, (ii) breadth of response, (iii) magnitude of response, & (iv) multi-re-use capability afforded by synthetic long-peptides.

HD-Antigens are naturally occurring viral peptides (35 amino acids) which are highly conserved across all viral strains and contain high density clusters of CD4 T-Helper and CD8 Cytotoxic T-Lymphocyte epitopes ensuring broad human population coverage. HD-Antigens are conjugated to a fl uorocarbon vector. Each vaccine contains multiple (6-8) HD-antigens as a freeze dried thermostable nanoparticle based formulation. Candidates for Hepatitis-B & C, HIV, HPV-cancer await development funding or partners.

MANAGEMENT

Senior ManagementCarlton Brown, CEO Campbell Bunce, R&D DirectorJill Makin, Head Vaccine Manufacture & CMCFinance Director (TBC)

Board of Directors Ken Powell, Chairman


AWARDS



WELCOM

ESPONSORS

back :: next

Kenta Biotech www.kentabiotech.com

CONTACTSMs Violetta GeorgescuChief Executive Offi cer

Ms Laurence BlazianuChief Business Offi cer

ADDRESSKenta BiotechRehhagstrasse 79Bern, 3018Switzerland

TELEPHONE+41 58 680 52 52

FAX+41 58 680 52 51

EMAILvioletta.georgescu @kentabiotech.comlaurence.blazianu @kentabiotech.com

YEAR FOUNDEDJanuary 2006

FINANCIAL SUMMARY

Kenta Biotech is a private company founded in 2006 and is headquartered in Berne, Switzerland. The company is fi nanced by independent private investors and management who together hold the company share capital. Kenta Biotech raised so far CHF 27 mio (series A+B).

COMPANY PROFILE

Kenta Biotech is pioneering the use of fully human antibodies to fi ght life-threatening hospital infections.

Kenta’s pipeline includes a series of 8 genuinely human antibodies to target the most diffi cult to treat pathogens causing life-threatening hospital infections, such as P. aeruginosa, S. aureus and A. baumannii. Kenta Biotech’s antibodies are intended as life-saving treatments for the most vulnerable patients in intensive care units.

Kenta’s fi rst-in-class, targeted therapies have the potential to revolutionise the treatment of hospital infections, to reduce mortality and to shorten hospital stays.

The company’s lead candidate panobacumab is a human IgM monoclonal antibody for the treatment of hospital-acquired pneumonia induced by P. aeruginosa. Panobacumab completed successfully it Phase IIa study. The clinical and microbiological outcomes indicate that panobacumab is safe and effi cacious. All patients receiving the full treatment cycle were cured and survived, despite a predicted mortality of 32% (based on APACHE II).

TECHNOLOGY

Kenta is the fi rst company to use genuinely human antibodies as they were intended by nature – to fi ght infection.

Kenta’s proprietary MabIgX® technology rapidly generates fully human antibodies that have been

already optimised by the human immune system. The MAbIgX® approach does not require any genetic engineering or modifi cations to the antibody – saving time and money. This technology enables the company to test therapeutically-promising antibodies against a variety of targets within a short period of time.

MANAGEMENT

Violetta Georgescu has over 25 years’ experience in the pharma/biotechnology industry as Executive. In her last assignment, she was responsible for the development of MabThera - rituximab.

Laurence Blazianu has 12 years’ experience in pharma. She worked in Global Marketing andPartnering at Roche before being Biotech/Pharma Analyst at Credit Suisse.


AWARDS



WELCOM

ESPONSORS

back :: next

London Genetics www.londongenetics.com

CONTACTSMs Dominique Kleyn Chief Executive Offi cer

Dr Elizabeth Foot Chief Scientifi c Offi cer

ADDRESSLondon Genetics LimitedImperial CollegeLondon SW7 2BPUnited Kingdom

TELEPHONE+44 (0)20 7594 1838

[email protected]@londongenetics.com

YEAR FOUNDED2007

COMPANY PROFILE

London Genetics is an expert in the use of pharmacogenetics in clinical drug discovery and development.

It works with London-based centres of excellence in genetic research to provide pharmacogenetic solutions.

London Genetics can help companies: • Partner with relevant academic and clinical genetics experts • Apply genetic knowledge to de-risk clinical trials • Design and manage projects • Store, analyse and interpret study data • Access comprehensive patient cohorts

TECHNOLOGY

Pharmacogenetics will play a key role in the future of drug development and healthcare delivery, with the biopharmaceutical industry coming under increasing pressure for greater innovation, productivity and safety.

By providing companies with access to the combined genetics expertise and resources of its seven academic institution partners, London Genetics can help them meet these challenges. The company has broad expertise areas across a range of therapeutic areas. It is based at the Imperial College Incubator in London, UK.

MANAGEMENT

The Company has an experienced Board chaired by Dr Barrie Ward and a Management team led by Dominique Kleyn. Chief Scientifi c Offi cer Dr Elizabeth Foot is joined by Clinical Director Professor Mark Caulfi eld, with Dr Roland Kozlowski and Professor Mike Spyer as non-executive directors.

Launched with funding from the London Development Agency and in partnership with London’s leading biomedical research facilities, medical schools and teaching hospitals, London Genetics unites and identifi es core strengths and resources among its partner institutions:

• Imperial College London • King’s College London • University College London • Queen Mary, University of London • St. George’s, University of London • London School of Hygiene and Tropical Medicine • The Institute of Cancer Research


AWARDS



WELCOM

ESPONSORS

back :: next

Lumavita AG www.lumavita.com

CONTACTSMr Nicholas BenedictChief Executive Offi cer

Dr Cees WinnipsChief Scientifi c Offi cer

ADDRESSLumavita AGHenric Petri Strasse 64051 Basel Switzerland

TELEPHONE+41 61 225 4102

FAX+41 61 225 4101


YEAR FOUNDEDAugust 2008

FINANCIAL SUMMARY

CHF 24 million (€16 million) Series A closed May 2009.

Investors include: Atlas Venture • BB Biotech Ventures • BioMedInvest • Endeavour Vision • HealthCap

COMPANY PROFILE

Lumavita is a privately-owned specialty biopharmaceutical company focused on global development and commercialisation of novel anti-infectives for Women’s Health.

Lumavita is uniquely positioned as the only specialty biopharmaceutical company dedicated to developing and marketing new molecular entities to combat infections for Women’s Health, addressing major therapeutic needs in large global markets. The company is based in Basel, Switzerland.

Lumavita’s proprietary portfolio contains one product recently approved in August 2009, one in clinical development and one in late-stage pre-clinical development.

Lumavita has established a network of partnerships with distributors for the launch of its fi rst product, expected during 2010. Lumavita retains all of the rights to its other products across all of the world’s key markets.

By focusing on well-defi ned gynecology market opportunities with new molecular entities, Lumavita has the opportunity to build a unique specialty biopharmaceutical company with a low risk profi le.

TECHNOLOGY

Lumavita’s fi rst product is low-dose FemiFect® (pentamycin), a broad spectrum macrolide for the treatment of vaginitis recently receiving Swiss Marketing Authorisation. FemiFect® is the fi rst anti-biotic for the treatment of all three cause of vaginitis, fungal infections, bacterial infections and protozoa.

Once established as fi rst-line empirical treatment in vaginitis, low-dose FemiFect® will be followed by a dose-optimised formulation, reducing the number of treatent days to three. Lumavita is currently undertaking a Ph IIB does-optimisation program in this regard.

Vaginitis is a very common disorder affecting around 10% of women every year and generating 110 million prescriptions in the core markets. Limitations with existing treatments result in many patients failing to respond adequately and recurrence rates of up to 40%.

Lumavita is in late-stage pre-clinical testing of LMV-601, the most advanced compound in a new class of anti-virals known as PC-PLC Inhibitors (phosphatidylcholine-specifi c phospholipase-C inhibitors). LMV-601 is being evaluated for its potential to treat cervical HPV, a currently untreated condition which preceeds nearly 100% of all cervical cancers.

MANAGEMENT

Lumavita has established a strong Management team by combining the anti-infective discovery and development expertise of Dr. Cees Winnips, Founder and CSO, with that of Mr. Nicholas Benedict, who has a signifi cant track record in commercialisation within the pharma and biotech inductries.


AWARDS



WELCOM

ESPONSORS

back :: next

Medical Device Works www.medicaldeviceworks.com

CONTACTSMr Joop FierensChief Executive Offi cer

Mr Herbert Köntges Chief Business Offi cer

ADDRESSMedical Device Works NVAvenue Joseph Wybranlaan, 40B – 1070 BrusselsBELGIUM

TELEPHONE+32 2 529 51 06

FAX+32 2 529 51 05

EMAILherbert.kontges @medicaldeviceworks.com

YEAR FOUNDED2004

FINANCIAL SUMMARY

Founders: 365 kEURFirst fi nancing round 2007: 3.500 kEUR, with: ODDO Asset Mgmt, Paris; Highland Star,Geneva; SRIW, Liège.Second fi nancing round planned 2010.

COMPANY PROFILE

MEDICAL DEVICE WORKS NV/ SA (MDW) specializes in the development and manufacture of minimally invasive devices for the isolation and perfusion of organs.

Medical Device Works is an ISO 13485 certifi ed and qualifi ed medical device company. It was founded as a Management-Buy-Out (MBO) from an international medical device company. In 2007, MDW received a worldwide patent on the Liver-PILP system and established a research cooperation with the Catholic University of Leuven Hospital on the clinical development of the Liver-PILP System. Animal tests were successfully concluded in 2009 and the company will start a human clinical study in 2010.

Other business activities of MDW are development services and OEM sub-manufacturing for prominent, international device companies.

TECHNOLOGY

The company is focusing on the development of a proprietary, disposable catheter-based system for the percutaneous isolation and perfusion of the liver for the treatment of primary and secondary liver cancer (Liver-PILP). The disposable PILP system temporarily occludes blood fl ow to and from the liver and permits local perfusion of the isolated liver with high doses of chemotherapy for a high tumor response with no (or minimal) systemic side effects. The percutaneous, interventional technique reduces morbidity, is cost effective, and permits the procedure to be done repeatedly per patient. The Liver-PILP can be used with any drug under any dosing regimen/ protocol. This business model allows for a shorter approval and reimbursement process, optimization of the treatment protocol for improved clinical results and opens strategic options for MDW to partner with drug manufacturers.

MDW owns proprietary techniques for fabricating covered wire braided endo-prostheses.

MANAGEMENT

Joop Fierens, CEOHerbert Köntges, Chief Business Offi cerAndré Khairallah, CFODr. Emmanuel Bartholomé, Medical Director

Head Medical Advisory BoardProf Dr Eric Van Cutsem, KU Leuven/Belgium


AWARDS



WELCOM

ESPONSORS

back :: next

Nabriva Therapeutics AG www.nabriva.com

CONTACTDr David Chiswell Chief Executive Offi cer

ADDRESSNabriva Therapeutics AGLeberstrasse 201110 ViennaAustria

TELEPHONE+43 174 093 1240

FAX+43 174 093 1900

[email protected]@nabriva.com

YEAR FOUNDEDFebruary 2006

FINANCIAL SUMMARY

€57 million equity raised. In addition, the company has also been awarded signifi cant grants and loans from Austrian public institutions.

COMPANY PROFILE

Nabriva Therapeutics was founded in February 2006 as a spin-out of Sandoz GmbH to develop Pleuromutilins, a new class of antibiotics for human therapy. The company raised Euro 42 Million in a Series A Financing Round. In October 2010 the company closed an additional Euro 15 Million fi nancing. Both rounds were led by Nomura Phase4 Ventures and included all the Company’s main shareholders Nomura Phase4 Ventures, HBM Partners, The Wellcome Trust, Global Life Science Ventures and Novartis Venture Fund.

DRUG PROTFOLIO

Pleuromutilins are unique antibacterial compounds that interfere with bacterial protein synthesis via a specifi c interaction with the 23S rRNA of the 50S bacterial ribosome subunit and address the signifi cant medical need for new antibiotic approaches to challenge serious infections in humans caused by multi-drug resistant pathogens.

Systemic Pleuromutilins: Our lead molecules can be administered orally and/or intravenously and have been demonstrated to be active against all clinically important bacteria that cause complicated skin and skin structure infections and community-acquired pneumonia (CAP) including MRSA. Importantly they are not affected by resistance generated against any other approved antibiotic.

MANAGEMENT

Executive ManagementDavid Chiswell, Chief Executive Offi cerRodger Novak, Chief Operating Offi cerRalf Schmid, Chief Financial Offi cerWilliam Prince, Chief Medical Offi cer

Supervisory BoardDenise Pollard-Knight (Chair), Nomura Phase4 VenturesAxel Bolte (Deputy Chair), HBM PartnersRobert C. Moellering, Harvard Medical SchoolAnja König, Novartis Venture FundGeorge Talbot, Talbot Advisors LLCPeter Reinisch (Observer), Global Life Science.


AWARDS



WELCOM

ESPONSORS

back :: next

Neovacs SA www.neovacs.fr

CONTACTSGuy-Charles Fanneau de La HorieChief Executive Offi cer

Piers Whitehead Vice-President,Corporate Development

ADDRESSNEOVACS SA3-5 Impasse Reille75014 ParisFrance

TELEPHONE+33 1 531 093 00

FAX+33 1 531 093 03


YEAR FOUNDED1993

FINANCIAL SUMMARY

2 fi nancing rounds by VCs have been completed, in 2003 and 2007 and a convertible bridge loan has recently been fi nalized.

Current investors are Truffl e Capital, Novartis Venture Fund and OTC asset management.

COMPANY PROFILE

Neovacs was founded in 1993 by Professor Daniel Zagury as a spin-off from Pierre and Marie Curie University (Paris VI). In 2003 Truffl e Capital provided the fi rst venture capital and a new management team was hired, shifting the focus to drug development. In 2006, Guy-Charles Fanneau de La Horie was hired as CEO. In 2007, Truffl e Capital, Novartis Venture Fund and OTC asset management invested in a B fi nancing round, totalling more than €18 million.

Neovacs has also received public funding for VEGF-K (Eureka), IFN-K (ANR) and more recently TNF-K (€6.4 million from ISI). The lead program, TNF-K, is currently in Phase I/II in Crohn’s Disease patients and was named as the most promising product in Phase II in 2008 by Thomson Reuters.

Recent scientifi c results have been presented at the EVER congress on VEGF-K in an animal model of age-related macular degeneration, at the ACR Congress on IFN-K in Lupus preclinical experiments and soon at the GASTRO 2009 congress on TNF-K in a Phase I/II clinical study in Crohn’s Disease.

TECHNOLOGY

Neovacs develops Kinoids, which are active immunotherapies targeting cytokines, for the treatment of severe auto-immune and chronic diseases. Intra-muscular injections of Kinoids elicit the secretion of polyclonal antibodies which neutralize the targeted cytokine responsible for the disease.

Kinoids are immunogenic heterocomplexes of the targeted cytokine conjugated to Keyhole Limpet Hemocyanin, a carrier protein, administered as an emulsion with an adjuvant, ISA 51.

MANAGEMENT

Senior ManagementGuy-Charles Fanneau de La Horie, Chief Executive Offi cerPierre Vandepapeliere MD, Ph.D., Chief Medical Offi cerPiers Whitehead, Vice-President, Corporate DevelopmentBernard Fanget, Ph.D., Vice-President, Pharmaceutical AffairsGéraldine Grouard-Vogel, Phar.D, Ph.D., Director R&D, PreclinicalOlivier Dhellin, Pharm D, Ph.D., Director, Manufacturing, QA

Board of DirectorsJean-Jacques Bertrand, ChairmanDirectorsPhilippe Pouletty, MD, Ph.D., Truffl e CapitalFlorent Gros, Novartis Venture FundMichel Gomart, OTC asset managementDaniel Zagury, MD, Ph.D., Founder, President of Scientifi c BoardThomas Kündig, MD, Ph.D., Hospital of ZürichRené Goedkoop, MD, Independent Consultant


AWARDS



WELCOM

ESPONSORS

back :: next

Nitec Pharma www.nitecpharma.com

CONTACTSMr Anders Härfstrand, Md Ph.D. Chief Executive Offi cer

Mr Harry WeltenChief Financial Offi cer

ADDRESSNitec Pharma AGCH-4153 ReinachSwitzerland

TELEPHONE+41 (0)61 715 20 40

[email protected]

YEAR FOUNDED2004

FINANCIAL SUMMARY

Nitec raised $10m in a Series A fi nancing round in 2004, when the Company was spun out of Merck KGaA. In March 2007, NGN Capital, as lead investor, Atlas Venture and Global Life Science Ventures subscribed to a CHF 32 million ($26m) Series B round of fi nancing. In October 2008 the company raised a further CHF 24 million with TVM as lead investor in addition to Deutsche Bank and the present investors.

COMPANY PROFILE

Nitec is a specialty pharma-ceutical company focused on the commercialisation and development of medicines to treat chronic infl ammation and pain-related diseases. It seeks to address areas of high unmet medical need within these markets by developing proprietary products based on well-characterised pharma-ceuticals and disease targets. The Company is a spin-out of Merck KGaA and is head-quartered in the Basel region of Switzerland. Since its formation in 2004, Nitec has developed and commercialised its lead product, Lodotra™. In January 2009, Lodotra™ was recommended for European regulatory approval for the treatment of rheumatoid arthritis (“RA”), particularly the associated and debilitating morning stiffness, following the successful completion of a phase III trial (CAPRA-1) in 2006. Germany was the Reference Member State and Lodotra™ is now also considered approvable by the regulatory agencies of 14 other countries under the Decentralised Procedure. In March Nitec announced a European partnership for Lodotra’s commercialisation with MundiPharma. Merck KGaA, which holds the distribution rights to Lodotra in Germany and Austria, have recently launched the product in Germany. Lodotra™ is a proprietary single-pulse night-time release formulation of low dose prednisone, a well-characterised glucocorticoid used in the treatment of a number of conditions including RA where it is used as a backbone treatment. A second pivotal phase III trial (CAPRA-2) was conducted in the US and the data will used to fi le for US-marketing approval with the FDA together with the data already available from the CAPRA-1 fi rst pivotal phase III trial. Nitec’s second product candidate, TruNoc™ is currently in clinical development for neuropathic pain and other chronic pain diseases.

TECHNOLOGY AND PRODUCT INFORMATION

Lodotra™ is a proprietary single-pulse night-time release formulation of low dose prednisone, a well-characterised glucocorticoid used in the treatment of a number of conditions including RA where it is used as a backbone treatment.

PARTNERING INTERESTS

In March 2009, Nitec signed an agreement with Mundipharma relating to the distribution rights to LodotraTM in Europe, excluding Germany and Austria which are licensed to Merck KGaA, and Nitec will receive undisclosed royalty payments. Nitec retains all commercialisation rights for the rest of the world. Nitec plans to commercialise its products in the US through out-licensing to partners. Nitec will explore partnership opportunities for TruNoc at a later stage.

CORPORATE HIGHLIGHTS

In September 2009 Nitec announced positive results from the second pivotal phase III trial (CAPRA-2) for Lodotra™. The 12-week, multicentre, double-blind phase III trial again demonstrated the safety and effi cacy of Lodotra™ in RA. 350 patients, all inadequate responders to DMARD therapy, received either Lodotra™ (5mg once daily), or placebo in addition to their existing therapy. Lodotra™-treated patients showed an ACR-20 response of 49% compared to 29% in the placebo group (highly signifi cant p=0.0002; LOCF). The reduction of morning stiffness was 44% in the Lodotra™ group (21 % in the placebo group).This difference was also highly signifi cant (p=0.0008). Lodotra™ was safe and well tolerated. These data strongly underline the benefi ts of Lodotra™. CAPRA-2 is the fi rst pivotal phase III study to demonstrate the ACR-20 response of a very low dose of prednisone as a primary endpoint.

.


AWARDS



WELCOM

ESPONSORS

back :: next

NOLabs AB www.nolabs.com

CONTACTSMr Patrick Schnegelsberg Acting Chief Executive Offi cer

Mr Tor Peters Chairman

Mr Lars LindgrenDirector, R&D

ADDRESSNOLabs ABRönnowsgatan 8S-252 25 HelsingborgSweden

TELEPHONE+46 42 33 65 32+972 54 613 5787

FAX+46 42 29 08 10


YEAR FOUNDED2005

FINANCIAL SUMMARY

Investors: Founders & Angels

Management is seeks to raise €10 million to fi nance planned phase II clinical studies, research and product development.

COMPANY PROFILE

Helsingborg/Sweden-based NOLabs AB is a privately held life-science company founded in 2005. The Company is engaged in the development and commercialization of its patented NitroSense® technology for the adminis-tration and controlled release of pure nitric oxide (NO) to treat neuropathic pain.

In 2009, the Company successfully completed a double-blind, placebo-controlled feasibility study with Nitro-Sense® Derma Protect enrolling 50 patients with diabetic peripheral neuropathy (DPN). This study demonstrated a statistically signifi cant reduction of neuropathic pain by NitroSense® Derma Protect. In addition, the trial showed that the product is safe, well tolerated and without systemic side-effects.

NOLabs is in discussion with the EMEA and US FDA and plans to start phase II clinical testing of its next genera-tion product, NitroSense® PA6, in 2010. The Company is also actively involved in dialogues with leading life science companies concerning co-development/commercialization partnership(s).

TECHNOLOGY

NitroSense® technology consists of an encapsulated nitric oxide generating polymer and an activation fl uid. Nitric oxide is generated immediately prior to use of a NitroSense® product by mixing the polymer with the activation fl uid. Activation and release of pure nitric oxide across a semi-permeable membrane occurs in a highly controlled manner and can be tightly regulated. Any impurities and by-products are retained. As a result, pure nitric oxide can be generated in-situ and the gas is released (delivered) at constant rates and levels for periods exceeding three hours. The Company owns an extensive patent portfolio and technical know-how covering NitroSense® technology and its applications.

MANAGEMENT

Patrick Schnegelsberg, Acting CEOTor Peters, Chairman


AWARDS



WELCOM

ESPONSORS

back :: next

NOXXON Pharma AG www.noxxon.com

CONTACTMr Frank Morich Ph.D.Chief Executive Offi cer

ADDRESSNOXXON Pharma AGMax-Dohrn-Str. 8-10Berlin, 10589Germany

TELEPHONE+49 30 726247-0

FAX+49 30 726247-225

[email protected]

YEAR FOUNDED1997

FINANCIAL SUMMARY

In 2007 NOXXON completed a EURO 37 million Series C fi nancing round. The investment was led by TVM Capital, Sofi nnova Partners, Edmond de Rotschild Investment Partners and Detsche Effecten – und Wechsel-Beteiligungsgesellschaft (DEWB). Additional investors included Seventure Partners, Dow Venture Capital, Dieckell Group, FCP OP MEDICAL BioHealth-Trends, IBG Risikokapitalfonds, VC Fonds Berlin and others.

COMPANY PROFILE

Berlin-based NOXXON Pharma AG is a clinical stage biotechnology company focusing on the development of Spiegelmers® for the treatment of infl ammatory diseases and hematological indications. NOXXON is in possession of a broad patent estate and has access to a readily scalable GMP production. In addition to its in-house programs, NOXXON discovers and develops Spiegelmers® in collaboration with partners from the pharmaceutical industry, including Eli Lilly, Hoffmann La-Roche, and Pfi zer. The business strategy of NOXXON is to broaden this range of collaborations through co-development and licensing agreements for the proprietary clinical and pre-clinical products as well as technology-based multi-target partnerships. Currently the company has two compounds in clinical development. The declared goal of NOXXON is to establish its oligonucleotide-based drug discovery platform (Spiegelmers®) as the leading ‘scaffold’ technology to create new chemical entities with superior properties.

TECHNOLOGY

NOXXON’s proprietary drug discovery platform is based on Spiegelmers®, short strands of single stranded mirror image RNA that fold into three-dimensional structures with inhibitory function. They are obtained through screening of libraries containing over 1015 molecules. Spiegelmers are highly selective for their target and have been shown to be extremely safe and well tolerated in numerous animal models and in phase I clinical trials. Their mirror image confi guration confers tremendous stability in all biological environments, overcoming the susceptibility to degradation by nucleases. Unlike antibodies Spiegelmers do not require cell-based manufacturing and are synthesized using well established, scalable processes.

NOXXON has successfully completed a phase I clinical trial with its MCP-1 inhibitor NOX-E36. The compound is in development for the treatment of diabetes related complications. The company conducts a phase I clinical trial with a second development candidate, NOX-A12 for use in autologous stem cell tranplantation. NOX-A12 is a potent inhibitor of the chemokine SDF-1.

MANAGEMENT

Dr Frank Morich, Chief Executive Offi cerDr Sven Klussmann, Chief Scientifi c Offi cer


AWARDS



WELCOM

ESPONSORS

back :: next

Pharmaneuroboost N.V. www.pharmaneuroboost.com

CONTACTSErik Buntinx, MDChief Executive Offi cer

Elly DaniëlsPersonal Assistant

ADDRESSPharmaneuroboost N.V.Alkerstraat 30A3570 AlkenBelgium

TELEPHONE+32 114 80750

FAX+32 114 84923

[email protected]

YEAR FOUNDED2006

FINANCIAL SUMMARY

PharmaNeuroBoost (PNB) is privileged to have a group of distinguished biotech investors.Collaboration with high value partners for co-development.

COMPANY PROFILE

PharmaNeuroBoost (PNB) - founded in 2006 - is a biopharmaceutical company dedicated to developing best in class CNS therapeutics. As such, PNB is specialized in boosting current standard of care on major psychiatric disorders with a high unmet medical need.

The two front-running proprietary projects (PNB01 and PNB02) are targeted against major depression and schizophrenia, respectively.

The innovative concepts of PNB exploit the benefi ts of ‘boosting’ effi cacy, based on a thorough mechanistic understanding of selective receptor involvement and receptor interplay at the CNS level.

These assets are directed at large unmet medical needs and major commercial markets.

Our drug candidates in different stages of clinical development, result from discoveries made using our unique IP platform claiming the use of high selective Serotonin 2A / Dopamine 4 receptor antagonists.

PNB’ Business Plan is oriented too collaboration with high value partners for co-development and/or commercialization of our late stage products.

TECHNOLOGY

The mechanism of action of PNB’s technology is based on the induction of a highly selective antagonism on the 5-HT2A and Dopamine-4 (D4) receptors in the CNS resulting in a boosting effect on the effi cacy of different psychotropics.

In antidepressants, this inhibits the specifi c and well-known negative feedback loops of antidepressants leading to a faster onset of action and a higher effi cacy; in antipsychotics and anti-parkinson drugs this will lead to a clinically signifi cant lowering of the burden of side effects.

Mechanism of Action in SSRI’s

Selective Serotonin Re-uptake Inhibitors (SSRIs), block the serotonin transporter responsible for pre-synaptic re-uptake of serotonin (5-HT). Thus the availability of serotonin at the synapse is augmented. This results not only in a therapeutic desensitization of the post-synaptic Ser 1A (=5-HT1A) receptor, but also an increase in the inhibition of the serotonergic neuron via the ser2A (=5 HT2A) receptor. This is a known negative feedback mechanism which is believed to be (partially) responsible for the low to moderate effi cacy of SSRIs.

For increase of action of SSRIs, it was postulated that 5-HT2A antagonists would be advantageous.

However, since 5-HT2A antagonists also induce an enhanced availability of dopamine leading to D4- receptor mediated behavioural deregulations, highly selective 5-HT2A antagonism needs to be accompanied by highly selective D4 antagonism.

Hence, there is a need for highly selective 5-HT2A / D4 antagonism to boost anti-depressive effi cacy.

Mechanism of Action in Atypical Antipsychotics (AP’s)

Based on clozapine’s outstanding effectiveness, a favourable 5HT2A/D2 receptor occupancy (RO) ratio combined with a favourable D4/D2 receptor occupancy ratio must lead to a best in class antipsychotic. Proof of Concept study results indicates that the combination of a highly selective 5-HT2A / D4 antagonist potentiates low dose antipsychotic effi cacy, closely mimicking the profi le of clozapine. As a result, PNB02 is expected to have a comparable effi cacy to clozapine but with a lower burden of side effects.

Continued...


AWARDS



WELCOM

ESPONSORS

back :: next

Pharmaneuroboost N.V. www.pharmaneuroboost.com

CONTACTSErik Buntinx, MDChief Executive Offi cer

Elly DaniëlsPersonal Assistant

ADDRESSPharmaneuroboost N.V.Alkerstraat 30A3570 AlkenBelgium


FAX+32 114 84923

[email protected]

YEAR FOUNDED2006

...Continued

MANAGEMENT

Senior ManagementErik Buntinx, MD-Psychiatrist, CEO / CSO – Managing Director

Dr Erik Buntinx, °1962, MD - Psychiatrist is Founder, Chief Executive Offi cer, Chief Scientifi c Offi cer and Managing Director of pharmaNeuroBoost N.V. (PNB).

He is an experienced psychiatrist who founded Anima Research Center, one of the largest outpatient psychiatric clinics with an integrated clinical research unit in Belgium and was former advisor of the WHO. He has developed knowledge database and patient management software.

Dr. Erik Buntinx has been Principal Investigator for various Phase IIa-III Clinical Trials for which he observed approximately 250 patients in total. He was involved in programs on Risperidone, Mianserine, Cycloserine, Sertraline, Escitalopram, Gaboxadol, several NK1-Antagonists and the very recently approved antidepressant agomelatine and antipsychotic asenapine.

He has been also developer of Investigator Initiated Trials in Delirium / Alzheimer and authority in CNS Drug Development. As such he is a frequently invited moderator and speaker at various B2B conferences and workshops.

Finally, he is the inventor of PNB’s IP platform on the use of high selective 5HT-2A/D4 Antagonists and achieved several granted patents in depressive, anxiety and psychotic disorders and also on Parkinson Disease.

He obtained his MD degree from the Catholic University of Leuven (KUL), Belgium and completed his psychiatric residency at the KUL and the University of Maastricht, The Netherlands, where he was a clinical and research resident before starting his private endorsements.

Ludo Haazen, MD, CMO

Dr. Ludo Haazen, MD, is Chief Medical Offi cer at PNB since November 2008. Starting his pharmaceutical career in 1988, he worked at diverse positions in national and International Clinical Research and Medical Affairs departments at Wellcome, Roche and the Janssen Research Foundation (JNJ), mostly in CNS. At Roche Ludo was involved in the international development of the antidepressant moclobemide and at JNJ he was Global Project Leader for phase I and II CNS compounds and Global Clinical Leader for the fentanyl transdermal system (Durogesic®). In 2003, Dr Haazen started a consultancy company (Envision bvba) and worked as consultant for several international pharmaceutical and biotech companies. As such, Ludo provided a major contribution to TiGenix in getting ChondroCelect® approved as the fi rst Advanced Therapy Product in Europe, supported International Medical Affairs activities for Neupro® (UCB), and was co-founder of and served as Chief Medical Offi cer for Reseda pharma NV, a start-up biotech company. At present, Dr Haazen is also acting as Qualifi ed Person for Pharmacovigilance.

Remi Van Den Broeck, MD, MSc, Senior Permanent Consultant Development

Dr. Remi Van Den Broeck, MD, Msc., has 29 years of drug development experience at Janssen Pharmaceutica NV, Medisearch and SGS Life sciences Founder, Chairman and CEO of Medisearch Int, a global CRO with 250 staff in Belgium, Spain and USA, later acquired by SGS Global Life Sciences.

His last position, before he went in to PNB, was Founder and Chief Development Offi cer of Movetis.

Scientifi c Advisory BoardPNB’s CEO / CSO Dr. Erik Buntinx was able to install an unrivaled world class SAB with Dr. Charles Nemeroff, Miami, Dr. Alan F. Schatzberg, Stanford and Dr. Th. Schlaepfer, Bonn.

The SAB is closely involved in:1. ongoing validation of the scientifi c concepts confi rming the clinical validity of the boosting concept,2. development and validation of clinical trial plans 3. assessing the potential for a multi-drug line opportunity

Charles Nemeroff, MD, Ph.D., the Leonard M. Miller Professor and Chair, Department of Psychiatry & Behavioral Sciences, University of Miami, Miller School of Medicine

Alan F. Schatzberg, MD, the Kenneth T. Norris Jr. Professor and Chair of the Department of Psychiatry and Behavioral Sciences at Stanford University, USA.

Thomas Schlaepfer, MD, Professor and Vice Chair of the Department of Psychiatry and Psychotherapy at the University of Bonn in Germany.


AWARDS



WELCOM

ESPONSORS

back :: next

Phylogica Ltd www.phylogica.com

CONTACTSDr Paul WattChief Executive Offi cer

Mr Gavin Rezos Investor Relations

ADDRESSPhylogica LtdPOSTAL: PO Box 8207 Subiaco EastWestern Australia 6008

COURIER: 100 Roberts Road, SubiacoWestern Australia 6008

TELEPHONE+61 8 9382 8888

FAX+61 8 9382 1766

[email protected]@viaticuscapital.com.au

YEAR FOUNDED2003

FINANCIAL SUMMARY

Public, traded on ASX

Shares on issue: 235.7 million

Capital Structure: 235.7 million Ordinary shares 22.69 million Options 1,340,000 notes (which can convert to 26.8 million shares)

Market Capitalization: Approximately US$30M.

Top 5 Shareholders hold 45% of Phylogica stock.

COMPANY PROFILE

Phylogica owns an emerging new class of proprietary therapeutics called Phylomer peptides.

Phylomer libraries are a particularly rich source of peptides which contain secondary and tertiary structure and which are more likely to bind targets with high affi nity than random peptides.

Phylogica helps partners discover peptides against intracellular or extracellular targets of interest, collaborating with a variety of companies, including J&J Research and Roche.

Phylogica is also using Phylomers to develop new classes of therapeutic peptides for infl ammatory diseases and for multi-resistant bacterial infections.

TECHNOLOGY

Phylomer peptides are fragments of naturally occurring proteins sourced from ancient bacteria from biodiverse sources. Phylomer libraries exhibit superior functional hit-rates, when compared to randomly derived peptides, due to an evolutionary selection of sequences over billions of years for enhanced structure and stability. Primary hits from Phylomer libraries can bind targets with picomolar affi nities, even prior to any sequence maturation. Phylomers can be used for target identifi cation and validation as well as potent drug leads.

Watt PM (2006) Nature Biotechnology 24 (2):177-83.

Watt, PM., Heinrich, TK., Thomas, WR. (2006); Protein Silencing with Phylomers: a new tool for target validation and generating lead biologicals targeting protein interactions. Expert Opin. Drug Discov. 1 (5):492-502

Watt, PM. Phenotypic screening of Phylomer peptide libraries derived from genome fragments, to identify and validate new

targets and therapeutics (2009). Future Medicinal Chemistry. 1 (2) 257-265.


AWARDS



WELCOM

ESPONSORS

back :: next

Prosensa www.prosensa.eu

CONTACTMr Hans SchikanChief Executive Offi cer

Mr Luc DochezChief Business Offi cer

ADDRESSProsensa Therapeutics BVWassenaarseweg 72Leiden, 2333 ALThe Netherlands

TELEPHONE+31 (0)71 332 2100

FAX+31 (0)71 332 2088

[email protected]@prosensa.nl

YEAR FOUNDED2002

FINANCIAL SUMMARY

Private company

Investors: Abingworth • AGF • Life Sciences Partners • GIMV • MedSciences Capital

COMPANY PROFILE

Prosensa is a biopharmaceutical company focused on the discovery, development and commercialization of RNA modulating therapeutics. The company targets genetic disorders with a large unmet medical need, with a primary focus on neuromuscular and neurodegenerative disorders such as Duchenne Muscular Dystrophy (DMD), Myotonic Dystrophy (DM1), Huntington’s Disease (HD) and Spinal Muscular Atrophy (SMA).

The company has developed a portfolio of clinical and pre-clinical RNA-based drug candidates. Prosensa’s current clinical portfolio is focused on the treatment of Duchenne Muscular Dystrophy. Its lead product, PRO051/GSK2402968, aims at restoring dystrophin expression and improving muscle condition and function in a relatively large subpopulation of Duchenne patients and has successfully completed a Phase I/II study. Preparations are ongoing to start enrolling patients in a Phase III study in 2010. PRO044, the company’s second product candidate, addresses another subpopulation of Duchenne patients and has entered clinical trials in the last quarter of 2009.

Prosensa was founded in 2002 and is located in Leiden, The Netherlands. The company works closely together with Leiden University Medical Center. In October 2009, Prosensa entered into a strategic alliance with GlaxoSmithKline (GSK) to accelerate and broaden the development of its DMD product candidates.

TECHNOLOGY

RNA-modulating therapeutics provide a powerful tool for targeted modulation of gene expression. Prosensa’s unique proprietary technology platform employs single-stranded RNA-based antisense oligonucleotides (AONs) to correct mutated mRNA causing life threatening disorders. In contrast to double-stranded RNA molecules such as RNAi, Prosensa’s AON technology, based on a rational sequence-specifi c design, offers a subtle, versatile, and allele-specifi c (re)engineering of RNA processing.

MANAGEMENT

Senior ManagementHans Schikan, CEOLuc Dochez, CBOGiles Campion, CMO


AWARDS



WELCOM

ESPONSORS

back :: next

ProtAffi n AG www.protaffi n.com

CONTACTSMr Dr Jason Slingsby Chief Executive Offi cer

Mr Dr Andreas KunglChief Scientifi c Offi cer

ADDRESSProtAffi n AGImpulszentrum Graz-WestReininghausstrasse 13aGraz, 8020Austria

TELEPHONE+43-316-382541

FAX+43-316-382541-4

EMAILjslingsby@protaffi n.comakungl@protaffi n.com

YEAR FOUNDED2005

FINANCIAL SUMMARY

ProtAffi n is well funded by an international syndicate of 5 venture capital funds in the US and EU. In April 2009, ProtAffi n completed a €14m ($20m) Series B fi nancing round co-led by SR One Ltd. and Atlas Venture. The Series A investors Aescap, Entrepreneurs Fund and Z-Cube also participated in the fi nancing.

COMPANY PROFILE

ProtAffi n AG is a European biotechnology company developing a novel class of biologics which target glycans in infl ammation and oncology. This is a novel therapeutic concept and is distinct to mAb and scaffold approaches. ProtAffi n is developing a glycan-binding IL-8 decoy protein for neutrophilic lung infl ammation (i.e. COPD). Our CellJammer® discovery platform has been used to develop further pipeline products which are also decoy chemokines with in vivo proof of concept data. The Company has 20 employees in Austria.

TECHNOLOGY

ProtAffi n AG is a biotechnology company developing anti-infl ammatory therapeutics that act by targeting cell-surface glycan structures driving acute and chronic infl ammatory diseases. ProtAffi n has developed the CellJammer™ discovery technology platform to develop protein-based products that interfere with protein-glycan interactions.

ProtAffi n’s lead anti-infl ammatory programme is PA401. PA401 is a modifi ed form of human IL-8 which is a potent, targeted anti-infl ammatory protein. The product binds to glycans that drive cellular infi ltration in infl ammation with a higher affi nity than wild-type IL-8. PA401 contains an amino acid deletion which means that unlike IL-8 it cannot activate leukocytes via the GPCR receptors CXCR1 and CXCR2. PA401 is in pre-clinical development at ProtAffi n for the treatment of neutrophilic lung infl ammation such as COPD. Composition of Matter patents for PA401 have been granted in the US and in the EU.

MANAGEMENT

ManagementDr Jason Slingsby, CEOProf Dr Andreas Kungl, CSO

Supervisory BoardKreske NickelsenDr Simon MoroneyDr Regina HoditsDr Deborah HarlandDr Brian MorganKlaas de Boer

Scientifi c Advisory BoardProf Robert HuberDr Timothy WellsDr Antal RotProf Timothy WilliamsProf John GallagherDr Marco SardinaProf Detlef Schlöndorff


AWARDS



WELCOM

ESPONSORS

back :: next

Savira Pharmaceuticals www.savira.at

CONTACTOliver SzolarChief Executive Offi cer/CSO

ADDRESSSavira PharmaceuticalsVeterinaerplatz 1, Building IA1210 ViennaAustria

TELEPHONE+43 1 25077 5904+43 664 8459742

FAX+43 1 25077 5999

[email protected]

YEAR FOUNDED2009

FINANCIAL SUMMARY

Seed capital.

COMPANY PROFILE

Savira Pharmaceuticals – located in Vienna, Austria – is focusing on the development of drugs for the treatment of infl uenza. Based on know-how and intellectual property from its co-founders, the European Molecular Biology Laboratory (EMBL) and the Vienna-based biotech company onepharm Research and Development GmbH, Savira will manage a focused portfolio of medicinal chemistry programs aiming at the identifi cation of lead candidates and the development of effi cacious and selective anti-infl uenza drugs.

Savira follows the biotech business model, turning capital and public grants into the preclinical and clinical development of a portfolio of anti-infl uenza drug candidates. Savira thus strives to create a sustainable pipeline, generate value for shareholders, improve quality of life for people suffering from infl uenza, and add to the arsenal of antivirals thus improving infl uenza pandemic preparedness.

Savira was founded by the EMBL, onepharm, private investors, and Savira’s management team.

TECHNOLOGY

Savira’s lead program is based on antiviral drugs, binding to defi ned active sites within the infl uenza virus polymerase directly inhibiting the transcription of the viral RNA genome in the nuclei of infected cells. The specifi c binding sites are involved in the “cap-snatching” mechanism, namely the cap-binding region and the active site of the viral endonuclease. The ultimate goal is to develop selective anti-infl uenza drugs overcoming the increasing emergence of resistance to the currently approved ion channel blockers amantadine and rimantadine and neuraminidase inhibitors oseltamivir (Tamifl u) and zanamivir.

Savira’s lead program is accompanied by a second development project exploiting the antiviral properties of substituted triterpenes which inhibit the entry of the infl uenza virus into the host cell.

MANAGEMENT

Senior ManagementOliver Szolar, CEO/CSODirk Claßen-Houben, Head Medicinal ChemistryAndrea Wolkerstorfer, Head Virology

Scientifi c Advisory BoardStephen Cusack, EMBL Klaus Klumpp, RocheHugo Kubinyi


AWARDS



WELCOM

ESPONSORS

back :: next

Scancell Holdings plc www.scancell.co.uk

CONTACTSProf Lindy DurrantChief Executive Offi cer

Dr Richard GoodfellowCommercial Director

ADDRESSScancell Holdings plcDept Clinical OncologyCity HospitalHucknall RoadNottingham, NG5 1PBUK

TELEPHONE+44 115 823 1863

FAX+44 115 823 1863

[email protected]

YEAR FOUNDED1996

FINANCIAL SUMMARY

Listed on UK PLUS market September 2008.

COMPANY PROFILE

Scancell is developing novel therapeutic vaccines for the treatment of cancer, based on its unique Immunobody® platform.

The company is listed on the UK PLUS Stock Exchange

The Company’s fi rst candidate vaccine, SCIB1, is being developed for the treatment of melanoma. The product is a plasmid DNA, which encodes a human antibody molecule engineered to express the melanoma antigen TRP2 plus two helper T cell epitopesderived from the melanoma gp100 protein. The major advantage of the Immunobody® technology is that the Fc component of the engineered antibody is recognised by the high affi nity CD64 receptor present on dendritic cells, leading to a signifi cant enhancement of both the frequency and avidity of the T cell immune response. SCIB1 is expected to enter Phase 1 clinical trials in April 2010.

The company is interested in partnering its Immunobody® platform technology to enhance the immune response to other cancer and infectious disease targets.

TECHNOLOGY

An ImmunoBody® is a human antibody or fusion protein engineered to express helper cell and CTL epitopes from tumour antigens over-expressed by cancer cells. Antibodies are ideal vectors for carrying T cell epitopes from tumour antigens as they have long half-lives and can effectively target dendritic cells via their Fc receptors, allowing effi cient stimulation of both helper and CTL responses.

By changing the expressed epitopes, the technology can be adapted to provide the basis for treating any tumour type and may also be of potential utility in the development of vaccines against hepatitis, HIV and other chronic infectious diseases.

MANAGEMENT

David Evans, ChairmanProf Lindy Durrant, CEODr Richard Goodfellow, Commercial Director


AWARDS



WELCOM

ESPONSORS

back :: next

Sensile Medical www.sensile-medical.com

CONTACTMr Derek BrandtChief Executive Offi cer

ADDRESSSensile MedicalFabrikstrasse 104614 HägendorfSwitzerland

TELEPHONE+41 (0)62 209 71 70

FAX+41 (0)62 209 71 01

[email protected]

YEAR FOUNDED2004

FINANCIAL SUMMARY

Privately owned company.

COMPANY PROFILE

Sensile Medical, founded in 2004, is a Swiss company with a global business strategy. Its research and development activities are focused on developing tools that help patients to better control their disease and improve the quality of their life.

Its core technologies comprise the development of new nanoliter-based medical devices that enable continuous glucose monitoring and micro drug delivery systems.

A sound patent strategy is protecting the company’s intellectual property. With the know-how, effi ciency and reliability of its employees, Sensile Medical makes sure that the interests of patients are well served. Sensile Medical collaborates in research and development with academic and industrial partners.

TECHNOLOGY

Sensile Medical is a Swiss product development medical device company with a line of drug delivery products and sensors for use in various therapeutic and clinical settings.

The pump technology is a novel device for subcutaneous drug delivery.

The pump technology combined three important advantages: Very cost effi cient, very precise and mass producible.

Sensile has 3 pump products under development: The Mini Pump is a classic (insulin) pump with a separate infusion set. The Patch Pump is a continuous delivery system in a patch. The Bolus Patch allows patients discrete drug delivery as bolus without the hassle of frequent injections.

MANAGEMENT

Mr Derek Brandt, CEOMr Helmut Thiemer, Head Pump DevelopmentDr Marco Gleichauf, Head of Quality Management & Regulatory Affairs


AWARDS



WELCOM

ESPONSORS

back :: next

Symphogen A/S www.symphogen.com

CONTACTMr Thomas FeldthusChief Finance Offi cer

ADDRESSSymphogen A/SElektrovejBuilding 375DK-2800 LyngbyDenmark


FAX+45 4526 5060

[email protected]@symphogen.com

YEAR FOUNDED2000

FINANCIAL SUMMARY

Symphogen has raised a total of €108 million in equity capital from a group of international investors including Essex Woodlands (US), Gilde Healthcare (The Netherlands), Tri Takeda (Japan), Novo A/S and LD Pension (Denmark).

COMPANY PROFILE

Symphogen is a private Danish biotech company with a subsidiary in Princeton, New Jersey.

Symphogen is developing superior antibody therapeutics to help people with serious diseases.

The company has a pipeline of internal and partnered products across multiple indications including cancer and infectious disease. The company’s lead product is in phase II clinical development.

The technology has been validated through partnerships agreements including a collaboration deal with Genentech for antibody therapeutics against three undisclosed infectious disease targets.

TECHNOLOGY

Symphogens technology platforms support the discovery and manufacture of recombinant antibody products – monoclonals or antibody mixtures.

MANAGEMENT

Kirsten Drejer, Chief Executive Offi cer Thomas Feldthus, Chief Financial Offi cerJoergen Petersen, Chief Development Offi cerSoeren Bregenholt, Chief Operating Offi cerAdriann Sax, Chief Business Offi cer


AWARDS



WELCOM

ESPONSORS

back :: next

TiGenix nvwww.tigenix.com

CONTACTSMr Gil BeyenChief Executive Offi cer

Mr Frank HazevoetsChief Finance Offi cer

Mr Kris Motmans Corporate Communications

ADDRESSTiGenix nvRomeinse straat 12/2B-3001 Leuven Belgium

TELEPHONE+32 16 39 6060

FAX+32 16 39 6050


YEAR FOUNDED2000

FINANCIAL SUMMARY

Up to date, TiGenix raised a total of EUR 89m. EUR 29m was raised in three venture rounds. In March 2007, the Company did its IPO on the Eurlist by Euronext Brussels, raising EUR 46m. IIn follow-on offerings in June and December 2009, TiGenix raised resp. EUR 5m and EUR 7.7m.

Key shareholders are ING Private Equity, Auriga Venture Partners, Fagus-Fortis Private Equity, Gemma Frisius Fund and van Herk.

COMPANY PROFILE

TiGenix is a late-stage biomedical company that focuses on innovative local treatments for damaged and osteoarthritic joints.

TiGenix is developing a portfolio of products that address specifi c musculoskeletal problems. The lead indication among these is cartilage damage, which is a debilitating affl iction affecting the mobility and functioning of patients. Western societies are characterised by ageing populations that place an increasing emphasis on high quality of life and life-long mobility, and, as such, cartilage problems represent a large and growing unmet medical need. Current therapies do not provide satisfying, long-term durable repair and TiGenix therefore believes there is a need for more effective treatments for cartilage damage.

ChondroCelect®, the company’s lead product for cartilage regeneration in the knee, is the fi rst cell-based product that successfully completed the entire development track from research, over clinical development to central European registration as a medicinal product. On October 5, 2009 ChondroCelect® received European marketing authorisation as the fi rst approved Advanced Therapy Medicinal Product (ATMP).

The company’s second product, Chondromimetic™, is an off-the-shelf, resorbable implant for the minimally invasive repair of small osteochondral defects. The product has received CE-Mark approval and is close to entering the European market. Chondromimetic forms an excellent fi t with ChondroCelect, since both products target the same customer base in complementary indications.

TiGenix’ headquarters are situated at the Researchpark of Haasrode (Belgium). The company has recently established a presence in Cambridge, UK. Furthermore, TiGenix has established production facilities in Leuven (Belgium) and in Memphis (TN, USA). The company is currently building a third production facility in Sittard-Geleen (The Netherlands).

TECHNOLOGY

TiGenix’ technology combines developmental engineering, biomaterials, stem cell technology and biological evaluation (in vitro and in vivo) of selected compounds in the treatment of osteoarthritis. The Company focuses on developing well-characterized, quality controlled cellular products with a predictable biological behavior and a proven effi cacy in vivo. The Company’s technology platform can be leveraged into more and broader applications, moving TiGenix’ products into the OA joints and other musculoskeletal tissues, based on the same and proven principles.

MANAGEMENT

Gil Beyen, Co-founder and CEOFrank Hazevoets, CFOWilfried Daelemans, CTOKoenraad Blot, CMOAndrew Lynn, CBOPatrick Haelterman, VP Sales & Marketing EU


AWARDS



WELCOM

ESPONSORS

back :: next

to-BBB technologies BVwww.toBBB.com

CONTACTSMr Willem van Weperen Chief Executive Offi cer

Mr Pieter Gaillard Chief Scientifi c Offi cer

Mr Hans van Rosendael Chief Finance Offi cer

ADDRESSto-BBB technologies BV Niels Bohrweg 112333 CA LeidenThe Netherlands

TELEPHONE+31 (0) 71 33 222 55

FAX+31 (0) 84 83 134 09

[email protected]@toBBB.com

YEAR FOUNDED2003

FINANCIAL SUMMARY

to-BBB is in the fi nal stages of a series-B investment of around €7-€8 million covering 2010 to 2012, which will allow completion of the Phase I/II study for brain cancer, and provide a base for a fi rst license deals with pharma partners.

COMPANY PROFILE

to-BBB is a Dutch biotechnology company in the fi eld of enhanced drug delivery across the blood-brain barrier. The company is developing novel treatments for brain disorders by combining existing drugs with its proprietary brain drug delivery platform. The company’s vision is that the treatment of currently unserved brain diseases will be best achieved by safely enhancing the blood-to-brain delivery of drugs.

to-BBB is headquartered in The Netherlands at the Leiden Bio Science Park and has established a fully owned subsidiary, to-BBB Taiwan Ltd., in Taipei, Taiwan.

TECHNOLOGY

G-Technology utilizes the endogenous ligand glutathione to deliver drug-loaded liposomes to the brain. This technology enables an enhanced transport of drugs across the blood-brain barrier and a better safety profi le and pharmacokinetic profi le compared to competing technologies. The G-Technology is already successfully validated in vitro and animal models for brain cancer, pain and viral encephalitis.

MANAGEMENT

Board of DirectorsPatrick KrolMats PetterssonJaap Blaak

Scientifi c Advisory BoardBert de Boer, PharmD, Ph.D.Prof Dr Herman de BoerDr Herbert HeynekerProf Dr Douwe BreimerProf Dr Rond de KloetProf Dr Joop van Gerven


AWARDS



WELCOM

ESPONSORS

back :: next

Wilex AGwww.wilex.com

CONTACTSPeter Llewellyn-DaviesChief Financial Offi cer

Katja Arnold Investor and Press Relations

ADDRESSWILEX AGGrillparzer Str. 1081675 Munich Germany

TELEPHONE+49 89 413138-126

FAX+49 89 413138-99

[email protected]

YEAR FOUNDED1997

FINANCIAL SUMMARY

Capital raised: Private funding: ~ €68 m; IPO 11/2006: ~ €55 m; Capital increase 02/2009: €10 m ; Capital increase 12/2009: €8.5 mListed: Frankfurt Stock exchange, Regulated Market (Prime Standard)Share Capital: approx. 15.96mMain Investors: dievini Hopp BioTech (29.0%), APAX Funds (13.3%), UCB Pharma (11.4%), TVM Funds (5.8%), Merlin Funds (5.4%), Management (1.9%), Free fl oat (33.3%).

COMPANY PROFILE

WILEX is an oncology focused bio¬pharmaceutical and is developing novel cancer therapies to provide effective and well tolerated treatment and enhance patients’ quality of life. WILEX’s product candidates are based on antibodies and small molecules. The late stage product portfolio includes both drug and diagnostic product candidates of which two are currently in pivotal Phase III trials.

TECHNOLOGY

WILEX’s technology is currently focused on three approaches:• Radio-labelled antibody designed to improve detection of tumours prior to surgery by means of high

precision imaging diagnostics;• Therapeutic antibody designed to make the tumour cells visible to the patient’s own immune system,

thereby allowing the patient’s own defences to destroy the tumour; and• Small molecule inhibition of the biological functions of a tumour to prevent the cancer cells from migrating

into the surrounding tissue to form metastases.

PIPELINE

Name Indication Phase Status

REDECTANE® Renal masses I I I Prelim. Ph IIII data in Q4/09,(antibody for Next: Final data in Q1/10,diagnostic use) Filing expected in 2010

RENCAREX® Non met. clear cell I I I Fully enrolled, Positive interim(antibody for renal cell cancer analysis for futility, Next: 343 eventstherapeutic use) triggers data point (2010)

MESUPRON® Pancreas cancer I I Impressive prelim. Ph II data in(uPA inhibitor) Q3/09 Next: Final data H1/10

MESUPRON® Breast cancer I I Next: Completion of patient (uPA inhibitor) enrolment

WX-554 Cancer I Dose escalation study (healthy (MEK inhibitor) volunteers) Next: Data H1/10

WX-037 Cancer Pre-clinical Development plan(PI3K inhibitor)

3 Antibody Cancer Pre-clinical Researchprogrammes*

PARTNERSHIPS

In January 2009 UCB and WILEX entered into a strategic alliance to develop UCB’s pre-clinical oncology portfolio. In July 2008, WILEX signed a worldwide marketing, distribution and sales agreement on REDECTANE® with Ion Beam Applications (IBA). In 2004, WILEX began a co-development and commercialization agreement for RENCAREX® with Laboratorios del Dr Esteve in certain countries in Southern Europe. WILEX plans to further commercialize its products through partnerships in particular MESUPRON® in 2010.

MANAGEMENT

Executive Management Supervisory BoardProfessor Olaf G. Wilhelm, CEO Dr David R. Ebsworth, ChairmanDr Paul Bevan, Head R&D Dr Georg F. Baur, Vice ChairmanPeter Llewellyn-Davies, CFO Professor Iris Löw-FriedrichDr Thomas Borcholte, CBO Dr Alexandra Goll Dr Rüdiger Hauffe Dr Friedrich von Bohlen und Halbach


AWARDS



WELCOM

ESPONSORS

AWARDS

Awards

The 3rd Annual European Life Science CEO Forum for Partnering & Investing is once again hosting the DyoDelta European Life Science Innovation Awards brought to you by DyoDelta Biosciences Ltd.. The awards recognise recent major investment and partnering deals within the industry and acknowledge organisations for their hard work, performance and achievements through their competitive business strategies, innovation and market leadership. The categories for these awards are:

• European Pharma Partner of the Year• European Pharma Deal of the Year• European Life Science Investor of the Year• European Financing of the Year

Our panel of expert judges who will be voting for the awards include:

• Dr Connie Fogarty, Vice President, Strategic Planning & Business Development, AstraZeneca

• Lubor Gaal, Director, Executive Director, Bristol-Myers Squibb

• Andrew Wood, Executive Director. Global External R&D for Europe, Eli Lilly & Co.

• Jose Maria Romero, Director Worldwide Business Development, GlaxoSmithKline

• Dr Margaret Beer, Director, Scientifi c Liaison, Licensing and External Research, Europe, Merck & Co

• Andrew Barber, Senior Licensing Manager, Merck Serono

• Ivica Cerina, Partner, NGN Capital

• Dr Esteban Pombo Villar, Head of Strategic Alliance Management, Novartis

• Massimo Radaelli, President & CEO, Noventia Pharma

• Dr Alex Chanas, Senior Director, Worldwide Licensing and Business Development, Pfi zer Inc.

• Michael Forer, Managing Director, Rosetta Capital

• Laurent Feniou, Director, Rothschild

• Dr Deborah Harland, General Partner, SR One

• Dr Ann Mills-Duggan, R&D Partnering & Business Development, UCB

• Christiane Verhaegen, CEO, Unibioscreen

The awards will be presented by Dimitri Dimitrio, CEO of DyoDelta Biosciences, and will take place on the 11th February at 18.15 in the Exchange Room, following the last panel discussion of the day.

The awards are being organised by DyoDelta Biosciences (www.dyodelta.com), a specialist advisory practice in deal making in the pharma and biotech sector.

DyoDelta EUROPEAN LIFE SCIENCE INNOVATION AWARDS


AWARDS



WELCOM

ESPONSORS

PARTNERING ORGANISATIONS

Partnering Organisations

next

www.bio-m.de

BioM is a service and consulting company whose aim is to promote the development of the Munich Biotech Cluster as an internationally renowned centre of excellence in the fi eld of innovative biotechnology. It is the fi rst point of contact for biotech start-up companies seeking fi nancial support or business advice. Through the BioM network which includes all important players in the region (representatives from public offi ces, scientifi c institutions, venture capitalists and biotech companies), BioM assists Munich-based companies in fi nding the right contacts and partners.

BioM Biotech Cluster Development GmbHAm Klopferspitz 19Ellipse - Haus Nr. 7, 3. Stock D-82152 Martinsried

Tel.: +49 (0) 89 89 96 79-0

BioM


AWARDS



WELCOM

ESPONSORS


back :: next


www.citigatedr.co.uk

Citigate Dewe Rogerson is the leading international consultancy specialising exclusively in fi nancial and corporate communications across the UK, Europe, North America and Asia.

Citigate has a dedicated Pharma & Biotech team with more than 60 years combined experience in the sector and a unique mix of skills: corporate and fi nancial PR and investor relations, fi nance, journalism and academic science. The team provides sector expertise and forms an integrated part of Citigate Dewe Rogerson, benefi ting from the company’s overall strength and from the cross-fertilisation of ideas across sectors.

The Citigate Pharma & Biotech team has an established track record in working with biotechnology companies at all stages in development. As well as core skills in fi nancial calendar work, transactions support, fi nancial PR and media relations, the team has extensive experience in branding, design and new media consultancy. Recent clients include global top-fi ve biotechs, listed companies in the UK and Europe, and numerous emerging businesses in the UK, France, Germany, the Netherlands, and Scandinavia.

Citigate’s Pharma & Biotech team has been involved in major corporate transactions such as IPOs, other public and private fundraisings, and M&As. We have advised on a number of IPO transactions across Europe including; METabolic EXplorer (Euronext Paris - €52 million), Algeta (Oslo Stock Exchange - €30 million), Santhera Pharmaceuticals (SWX – CH88.5 million), ThromboGenics (Euronext Brussels - €35 million), Hutchison China MediTech (AIM - £40 million), Zentiva (LSE and PSE – US $211 million), Arpida (SWX - €63 million), Inion (LSE - £35 million), TopoTarget (CSE - €30 million), BioFusion (AIM - £8.2 million) and ExonHit (Alternext - 7.3 million).

Citigate Dewe Rogerson3 London Wall BuildingsLondon WallLondon EC2M 5SY

Tel: +44 (0)-207-638-9571

Citigate Dewe Rogerson


AWARDS



WELCOM

ESPONSORS


back :: next


www.collegehill.com/lifesciences

College Hill Life Sciences provides a full service communications consultancy focused on science-based sectors. Within the life science fi eld we have established a leadership position by working in partnership with our clients to deliver high quality communications that build corporate value and promote leading edge products, technologies and services).

London Sue CharlesThe Registry, Royal Mint Court, London EC3N 4QN, UKT: +44 (0)20 7457 2020 F: +44 (0)20 7866 7900Email: [email protected]

Manchester Dr Eileen Paul / Chris Fisher Meadowside, Mountbatten Way, Congleton, CW12 1DN, UKTel: +44 (0)1260 296500 Fax: +44 (0)1260 296501Email: [email protected]

MunichDr Douglas PretsellAugustenstraße 79, 80333 Munich, GermanyTel: +49 (0)89 57 00 18 06 Fax: +49 (0)89 52 38 80 06Email: [email protected]

San Francisco Erik Clausen201 Spear Street, Suite 1100, San Francisco CA 94105, USATel: +1 (415) 230 5385Email: [email protected]

College HillLife Sciences


AWARDS



WELCOM

ESPONSORS


back :: next


www.goingpublic.de

Founded in1998 GoingPublic Media AG is today one of the leading publishers of magazines on technology trends, corporate fi nance and capital markets. 70-80 magazines, newsletters and books are being edited, printed and distributed each year. In addition to the monthly issued “GoingPublic Magazin” and its well known yearly special editions like “Corporate Finance & Private Equity Guide” or “Biotechnology” which are largely meant as reference books, the company publishes the likewise monthly “VentureCapital Magazin” (www.venturecapital.de). It stands as a hub for the private equity and venture capital industry in German speaking Europe and addresses investors and entrepreneurs who focus on trends in technology, corporate fi nancing and venture capital/private equity. Special topics are additionally treated in supplements and special editions (“Tech-Guide”, “Start-up” a.o.). Since 2003, GoingPublic Media AG addresses retail investors via its subsidiary Smart Investor Media GmbH and the monthly issued magazine Smart Investor. The quarterly published “HV Magazin” focuses on organizational, technical und legal trends concerning the annual shareholder meeting and is directed to the responsibles of listed companies (CFOs, investor relations managers etc.). New in 2007 is “Unternehmeredition”, which focuses quarterly on Small and Medium-sized Business Entrepreneurs. Furthermore GoingPublic Media operates the corporate publishing division GoingPublic Services. About 10 magazines and newsletters are annually distributed on behalf of well-known venture capital companies and fi nancial institutions. Since November 2006 GoingPublic Media is listed in the open market of Frankfurt stock exchange. The complete prospectus can be found at www.goingpublic.de/ir.

All publications are published in German.

Contact:GoingPublic Media AGBahnhofstr. 2682515 WolfratshausenGermany

Markus Rieger, CEOTel.: +49 (0) 8171/4196-50; [email protected]

Websites: www.goingpublic.de, www.vc-magazin.de, www.hv-magazin.de, www.smartinvestor.de, www.unternehmeredition.de

Going Public Media AG


AWARDS



WELCOM

ESPONSORS


back :: next


www.pharmadeals.net

Whether you require data for benchmarking, competition analysis or simply to fi nd out what new intellectual properties are being licensed, PharmaDeals® gives you access to the latest deal making information in the pharmaceutical and biotech fi eld. Intelligently indexed, the new PharmaDeals v2 database is the ultimate benchmarking tool.

PharmaDeals is brought to you by PharmaVentures, Experts in Deals and Alliances.

With PharmaDeals v2, you benefi t from using this unique set of business tools that offers you a fl exible and cost effective resource to assist you in your deal making activities:

• Empower your business decision makers: Use information from PharmaDeals v2 to assist with mission-critical or high risk decisions

• Unrivalled benchmarking tool - intelligently indexed and compiled to international standards by the experts in deals and alliances

• Save time and money: this is an outstanding research tool

• Track competitors’ deal activities

• Analyse what is happening in your deal arena

• Quickly and cost-effectively access detailed industry intelligence, through PharmaDeals Review (ISSN 1756-7874 - online publication) included in your PharmaDeals v2 subscription

Find out more about PharmaDeals: www.pharmadeals.net

If you would like to request a demonstration of PharmaDeals v2, please contact Silvia Serra on +44 (0) 1865 784 195 or e-mail [email protected].

PharmaDeals® is a registered Trade Mark of PharmaVentures Ltd.

PharmaDeals


AWARDS



WELCOM

ESPONSORS


back :: next


www.tiberendstrategicadvisors.com

Tiberend Strategic Advisors, Inc. is a corporate communications fi rm providing media strategy and execution for life science companies – biotech (therapeutics), medical devices and diagnostics. We work with both public and private emerging growth companies.

1. To enhance valuation

2. To build visibility for partnerships and strategic alliances

Tiberend Strategic Advisors, Inc.35 W. 35th Street, 5th Floor, New York, NY 10001-2205

Tel: 212.827.0020 Fax: 212.827.0028 Fax

Tiberend Strategic Advisors, Inc.


AWARDS



WELCOM

ESPONSORS


Supporting Organisations

back :: next

www.cfpartners.com

CFP BioConnect AG is a specialised consulting group in the Life Sciences sector. Founded in 1999, the company is focused on fi nancial and strategic advisory services for Life Sciences companies in the areas of biotechnology, diagnostics, pharmaceuticals and medical technology. Due to its comprehensive network and a highly motivated team of experienced specialists in the fi elds of Finance/M&A, Venture Capital and Life Sciences, CFP BioConnect AG has established itself as a leading advisory fi rm in the sector. CFP BioConnect AG’s track record comprises more than 20 funding rounds and numerous strategic advisory mandates, including M&A. This enabled the company to become a reputable partner for Life Sciences companies with needs for fi nancing or M&A advice.

For further information please refer to www.cfpartners.com

Klaus [email protected]

Corporate Finance PartnersCFP BioConnect AGNiedenau 3660325 Frankfurt/Germany

Tel.: +49 (0)69 90 74 66 0Fax: +49 (0)69 90 74 66 20

Corporate Finance PartnersCFP BioConnect AG


AWARDS



WELCOM

ESPONSORS


back :: next

Supporting Organisations

Objective Capital is an independent provider of corporate investment research. Our clients are companies, or their advisors, that are either private, publicly listed, or in the process of preparing for listing.

Objective’s life sciences research, produced regularly, and disseminated widely is an essential investment and communications tool. Sponsoring research is the most effective way for a company to build the strategic relationship it needs with the market to access investment funds, potential partners and ensure market interest in its stock. It also sends a strong message to potential investors that the company is committed to an open and transparent relationship with the market and ensuring that there will be a regular fl ow of investment research available.

Readers of our research include individuals, professional investors, fund managers, family offi ces and corporations, who have a private or professional interest in being informed about life science opportunities.

For more information please contact:Gabriel Didham, CFAUK: Mainline +44-870-080 2965 Direct: +44-20-7073 2693US toll free: 1-888-802 7215

[email protected]

Objective Capital www.ObjectiveCapital.co.uk

AWARDS

PARTNERING ORGANISATIONSPRESENTING COM

PANIESREGIONAL PARTNERS

ORGANISERSSPEAKERS

WELCOM

ESPONSORS

REGIONAL PARTNERS

Regional Partners

next

www.biotop.de

Investing in the life sciences

BioTOP Berlin Brandenburg is the central contact and coordination offi ce for all issues concerning biotechnology in the German capital region.

It is our objective to coordinate all regional activities in biotechnology by networking with all key players and to initiate specifi c projects in order to turn Berlin-Brandenburg into a globally leading life science cluster.

The services provided by BioTOP include:

• Technology transfer science - industry

• Initiation and support of networks

• Support for technology-oriented start-ups

• Funding support for innovative projects

• Providing information on biotechnology

• Building and coordination of scientifi c and interdisciplinary networks

• Establishing contacts between experts from all disciplines

• Design and organization of events

• Public relations work for the biotech region Berlin-Brandenburg

For more information, including a database with comprehensive profi les of all companies and scientifi c work groups, please visit our website at www.biotop.de.

Dr. Kai Bindseil BioTOP Berlin-BrandenburgFasanenstr. 8510623 Berlin - Germany

Tel: +49 30 318 622 11Fax + 49 30 318 622 22

BioTOP Berlin-Brandenburg

AWARDS



ORGANISERSSPEAKERS

WELCOM

ESPONSORS

REGIONAL PARTNERS

back :: next

Regional Partners

www.swedenbio.com

SwedenBIOs commitment is for a successful Swedish life science industry

SwedenBIO is the only national organization working for the benefi t of the entire life science industry in Sweden. SwedenBIO is a truly member driven, private non-profi t organization. The main objective is to improve and maintain industry conditions which will support prosperous growth and business development among our, today, 190 member companies. Our members are active in all sectors ranging from R&D, biotech, medtech to pharmaceuticals, diagnostics and biotech tools to service providers as CROs.

Our mission is to create visibility and interest for the Swedish life science industry and thereby support a successful life science industry. Life science is about “a reason to hope”. A successful industry can heal and help those patients still suffering from unmet medical needs. A successful industry creates jobs and welfare and creates enormous opportunities for a healthier and brighter future.

We listen to our members, respond and act. Our main platform for interaction with opinion leaders, decision and policy makers is our six industry working groups. These working groups comprise top executives from our member companies with excellent expertise and interests in a wide range of key industry topics.

SwedenBIO values the dialogue with key stakeholders in industry, academia, government, fi nancial and media community. We interact regularly with leading decision and opinion makers to support them in securing and capturing the full potential within life science in Sweden. It is our role to be an active and strong representative for the industry to stakeholders such as government, parliament, media, investors and the public community.

SwedenBIO represents and co-operates with other Swedish, European and international organizations with similar interests. SwedenBIO represents Sweden in the European industry organization EuropaBio and is an affi liate member in BIO, the US industry organization.

SwedenBIO was founded in May 2002 by the CEOs of seven leading Swedish life science companies including Amersham Biosciences (now GE Healthcare), Active Biotech, Biovitrum.

SwedenBioWallingatan 24111 24 StockholmSweden

Tel: + 46(0)8 21 36 02Fax: +46(0) 8 21 36 04

SwedenBio

AWARDS



ORGANISERSSPEAKERS

WELCOM

ESPONSORS

REGIONAL PARTNERS

Regional Partners

back

www.swissbiotech.org

One Nation – One Biotech Cluster

Swiss Biotech unites the leading biotech regions of Switzerland (BaselArea, Berne Capital Area, BioAlps, Biopolo Ticino and Greater Zurich Area). The regions have early on combined efforts with the SWX Swiss Exchange which holds a leading position in terms of life-science listings and services.

The National Industry Association named Swiss Biotech Association representing next to 200 companies to date and acting as the operational arm for the marketing alliance and the Medical Cluster complete the alliance.

Swiss Biotech raises Switzerland’s profi le as an economic center in Europe and profi les the biotech industry with its key research institutions and companies.

Swiss Biotech’s mission is to spread the message of Switzerland as one of the top biotech locations in the world. The cornerstones for success are the critical mass of research institutes and accelerated technology transfer. The early integration of industry and well-trained workforce is another critical success factor for rapid eco nomic growth. More than 40 technology parks throughout the country support the successful knowledge and tech-transfer.

Further inquiries:SwissBiotechExecutive Offi ce Tel. +41 (0)44 455 56 78

SwissBiotech

REGIONAL PARTNERSAW

ARDSPARTNERING ORGANISATIONS

ORGANISERSSPEAKERS


WELCOM

ESPONSORS

ORGANISERS

Organisers

www.sachsforum.com

Sachs Associates is a London-based company, which organises and produces securities and emerging marketsconferences in association with major exchanges and news agencies. Sachs Associates is dedicated to thehighest quality standards in conferencing and, as a result, produces only a limited number of events each year.Sachs Associates investment conferences focus on Emerging Markets, European Equities and Technology, andare held in major fi nancial centres such as London, New York and Zurich. Sachs Associates is focused on thepractical benefi ts accruing from conference participation, the exchange of ideas and information, and thefacilitating of business transactions.

The benefi ts of conference participation with Sachs Associates may be summarised as follows:

Multimedia ExposureSachs Associates is able uniquely to provide its conference sponsors maximum exposure across extremely wellfocused electronic and print media. Regular extensive coverage of all the Company’s conferences is carried out through video streaming and extensive events coverage through major international fi nancial news agencies,including Bloomberg, Dow Jones and Reuters. In addition, Sachs Associates has a number of long establishedrelationships with other fi nancial press organisations globally, which allow further effective distribution onbehalf of its clients.

Eminent SpeakersSachs Associates is committed to ensuring that its events continue to provide forums with the participation ofthe most eminent speakers from the public and private sectors. Through its reputation and its long-establishedlocal relationships, the Company has attracted the very senior political and economic personalities as speakersat its events.

Sponsorship and Marketing Opportunities for forthcoming eventsSachs Associates has developed an extensive knowledge of the key individuals operating within the Europeanand global biotech industry. This together with a growing reputation for excellence puts Sachs Associates at theforefront of the industry and provides a powerful tool by which to increase the position of your company in thismarket.

Sponsorship of any of our events allows you to raise your company’s profi le directly with your potential clients.All of our sponsorship packages are tailor made to each client, allowing your organisation to gain the most outof attending our industry driven events.

The following sponsorship and marketing opportunities are available at future conferences:• Conference Sponsor – including workshops and social events• Exhibition stands• Distribution of Promotional Material

Some of our more recent sponsors include:SWX Swiss Exchange, the London Stock Exchange, Standard & Poors and the American Stock Exchange, as wellas several major international investment banks and money managers.

If your company is interested in exhibition or sponsorship opportunities please callRosa Lippard on +44 20 7405 5544.

Sachs Associates


AWARDS



WELCOM

ESPONSORS

www.sachsforum.comEU

RO

PE

AN

L

IF

E

SC

IE

NC

E

CE

O

FO

RU

M

Oldebourne House46-47 Chancery LaneLondon WC2A 1JB UK

Tel: +44 (0)20 7405 5544Fax: +44 (0)20 7405 4411

3rd Annual EUROPEAN LIFE SCIENCE CEO FORUM · audience of over 400 investors, analysts & media,...

Documents

Transcript of 3rd Annual EUROPEAN LIFE SCIENCE CEO FORUM · audience of over 400 investors, analysts & media,...